Pressure BioSciences (PBIO) 10-Q 21 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 18, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38185
Entity Registrant Name	PRESSURE BIOSCIENCES, INC.
Entity Central Index Key	0000830656
Entity Tax Identification Number	04-2652826
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	14 Norfolk Avenue
Entity Address, City or Town	South Easton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02375
City Area Code	(508)
Local Phone Number	230-1828
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,068,187

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 230,880	$ 132,311
Accounts receivable	166,314	154,746
Inventories, net of $342,496 reserve at September 30,2022 and December 31, 2021	1,386,527	1,147,554
Prepaid expenses and other current assets	218,476	422,617
Total current assets	2,002,197	1,857,228
Investment in equity securities	51,929	59,976
Property and equipment, net	111,884	115,846
Right of use asset leases	313,564	395,565
Intangible assets, net	360,577	403,846
TOTAL ASSETS	2,840,151	2,832,461
CURRENT LIABILITIES
Accounts payable	608,054	527,924
Accrued employee compensation	221,938	117,680
Accrued professional fees and other	2,435,910	1,955,672
Accrued interest and dividends payable	9,929,179	7,757,217
Deferred revenue	127,091	37,124
Convertible debt, net of unamortized debt discounts of $434,313 and $1,536,649, respectively	16,708,661	12,839,813
Other debt, net of unamortized discounts of $0 and $0, respectively	1,555,775	1,256,840
Related party, net of unamortized debt discount of $19,149 and $0, respectively	565,501
Operating lease liability	141,649	132,996
Total current liabilities	32,293,758	24,625,266
LONG TERM LIABILITIES
Long term debt	150,000	150,000
Operating lease liability – long term	171,915	262,569
Deferred revenue		3,587
TOTAL LIABILITIES	32,615,673	25,041,422
COMMITMENTS AND CONTINGENCIES (Notes 4)
STOCKHOLDERS’ DEFICIT
Series D, G, H, H2, J, K, AA Convertible Preferred Stock, $.01 par value (Note 6)	1,098	1,099
Common stock, $.01 par value; 100,000,000 shares authorized; 12,220,611 and 9,120,526 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively	122,207	91,206
Warrants to acquire common stock	31,995,762	31,715,154
Additional paid-in capital	67,041,489	64,261,048
Accumulated deficit	(128,936,078)	(118,277,468)
Total stockholders’ deficit	(29,775,522)	(22,208,961)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 2,840,151	$ 2,832,461

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Inventory valuation reserves	$ 342,496	$ 342,496
Other debt, unamortized discounts net	$ 0	$ 0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	12,220,611	9,120,526
Common stock, shares, outstanding	12,220,611	9,120,526
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Series G Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series H Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series H2 Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series J Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series K Convertible Preferred Stock [Member]
Preferred stock, par value	0.01	0.01
Series AA Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Convertible Debt [Member]
Debt instrument, unamortized discount	$ 434,313	$ 1,536,649
Related Party [Member]
Debt instrument, unamortized discount	$ 19,149	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Products, services, other	$ 144,032	$ 518,365	$ 1,122,169	$ 1,687,166
Total revenue	144,032	518,365	1,122,169	1,687,166
Costs and expenses:
Cost of products and services	126,203	258,170	742,707	771,105
Research and development	262,370	282,622	716,685	839,072
Selling and marketing	226,526	66,068	422,422	252,209
General and administrative	892,293	1,154,063	2,591,644	2,788,779
Total operating costs	1,507,392	1,760,923	4,473,458	4,651,165
Operating loss	(1,363,360)	(1,242,558)	(3,351,289)	(2,963,999)
Other (expense) income:
Interest expense, net	(2,034,021)	(3,330,101)	(6,448,771)	(11,524,306)
Unrealized (loss) gain on investment in equity securities	(8,675)	(162,071)	(8,047)	(404,451)
Gain (loss) on extinguishment of liabilities	(1,054,122)	(277,010)	(1,809,249)	(1,500,395)
Other income (expense)	(2,059)	60,627	(904)	119,280
Total other expense	(3,098,877)	(3,708,555)	(8,266,971)	(13,309,872)
Net loss	(4,462,237)	(4,951,113)	(11,618,260)	(16,273,871)
Deemed dividends on beneficial conversion feature		(815,914)		(873,798)
Preferred stock dividends	(431,709)	(432,149)	(1,295,566)	(1,239,535)
Net loss attributable to common shareholders	$ (4,893,946)	$ (6,199,176)	$ (12,913,826)	$ (18,387,204)
Basic and diluted net loss per share attributable to common shareholders	$ (0.44)	$ (0.82)	$ (1.24)	$ (3.02)
Weighted average common shares outstanding used in the basic and diluted net loss per share calculation	11,131,742	7,561,728	10,429,817	6,083,017

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,618,260)	$ (16,273,871)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on loan forgiveness	(10,000)	(367,039)
Non-cash lease expense	82,001	48,158
Common stock and warrants issued for interest and extension fees	2,196,278	6,208,696
Depreciation and amortization	67,985	83,531
Accretion of interest and amortization of debt discount	1,777,863	5,308,424
Loss on extinguishment of accrued liabilities and debt	1,809,249	23,004
Stock-based compensation expense	128,984	219,943
Loss on investment in equity securities	8,047	404,451
Common stock and warrants issued for services	367,370	579,512
Changes in operating assets and liabilities:
Accounts receivable	(11,568)	(407,404)
Inventories	(238,973)	(203,651)
Prepaid expenses and other assets	204,141	(306,024)
Accounts payable	80,130	(336,675)
Accrued employee compensation	104,258	39,801
Operating lease liability	(82,001)	(48,158)
Deferred revenue and other accrued expenses	2,083,239	943,400
Net cash used in operating activities	(3,051,257)	(4,083,902)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(20,754)	(4,503)
Net cash used in investing activities	(20,754)	(4,503)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from Series AA Convertible Preferred Stock		1,015,000
Proceeds from stock option exercises	17,443	14,773
Net proceeds from convertible debt	3,428,249	5,054,500
Net proceeds from non-convertible debt - third party	1,815,000	1,610,688
Net proceeds from non-convertible debt - related party	762,500	194,600
Payments on convertible debt	(1,086,946)	(1,608,295)
Payments on non-convertible debt - related party	(259,600)	(256,600)
Payments on non-convertible debt	(1,506,066)	(1,291,150)
Net cash provided by financing activities	3,170,580	4,733,516
NET INCREASE IN CASH AND CASH EQUIVALENTS	98,569	645,111
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	132,311	18,540
CASH AND CASH EQUIVALENTS AT END OF PERIOD	230,880	663,651
SUPPLEMENTAL INFORMATION
Interest paid in cash	938,451	802,084
NON CASH TRANSACTIONS:
Common stock issued for non-cash warrant exercise		363
Early adoption of ASU 2020-06 adoption	473,027
Common stock issued with debt	512,593	551,198
Discount from warrants issued with debt	93,576	1,403,546
Common stock issued in lieu of cash for dividend	306,333	114,298
Preferred stock dividends	1,295,566	1,239,535
Conversion of debt and interest into common stock	350,500	2,589,990
Discount due to beneficial conversion feature		1,231,528
Deemed dividend - beneficial conversion feature		873,798
Conversion of accrued liabilities and debt for Series AA preferred stock		500,250
Conversion of preferred stock into common stock	$ 44

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholder's Deficit (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Warrant [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 1,093	$ 41,683	$ 29,192,471	$ 50,312,968	$ (96,465,807)	$ (16,917,592)
Beginning balance, shares at Dec. 31, 2020	109,272	4,168,324
Stock-based compensation				61,237		61,237
Series AA Preferred Stock dividend					(403,215)	(403,215)
Issuance of common stock for services		$ 1,124		237,388		238,512
Issuance of common stock for services, shares		112,400
Conversion of debt and interest for common stock		$ 472		117,528		118,000
Conversion of debt and interest for common stock, shares		47,200
Issuance of common stock for interest paid-in-kind		$ 9,224		2,012,556		2,021,780
Issuance of common stock for interest paid in kind, shares		922,372
Warrants issued with debt			162,654			162,654
Net loss					(6,577,587)	(6,577,587)
Stock option exercise		$ 214		14,559		14,773
Stock option exercise, shares		21,411
Issuance of common stock warrants for interest and paid-in-kind			600,298			600,298
Beneficial conversion feature on debt				53,777		53,777
Series AA Preferred Stock offering			49,884	50,116		100,000
Series AA Preferred Stock offering, shares	40
Beneficial conversion option on convertible preferred stock				57,884		57,884
Deemed dividend on convertible preferred stock				(57,884)		(57,884)
Ending balance, value at Mar. 31, 2021	$ 1,093	$ 52,717	30,005,307	52,860,129	(103,446,609)	(20,527,363)
Ending balance, shares at Mar. 31, 2021	109,312	5,271,707
Beginning balance, value at Dec. 31, 2020	$ 1,093	$ 41,683	$ 29,192,471	50,312,968	(96,465,807)	(16,917,592)
Beginning balance, shares at Dec. 31, 2020	109,272	4,168,324
Common stock issued for debt extension, shares		200	1,558,266
Net loss						(16,273,871)
Ending balance, value at Sep. 30, 2021	$ 1,099	$ 83,451	$ 31,607,879	62,307,524	(113,979,213)	(19,979,260)
Ending balance, shares at Sep. 30, 2021	109,878	8,345,120
Beginning balance, value at Mar. 31, 2021	$ 1,093	$ 52,717	30,005,307	52,860,129	(103,446,609)	(20,527,363)
Beginning balance, shares at Mar. 31, 2021	109,312	5,271,707
Stock-based compensation				63,458		63,458
Series AA Preferred Stock dividend					(404,171)	(404,171)
Conversion of debt and interest for common stock		$ 925		230,325		231,250
Conversion of debt and interest for common stock, shares		92,500
Issuance of common stock for dividends paid-in-kind		$ 560		113,738		114,298
Issuance of common stock for dividends paid-in-kind, shares		56,067
Issuance of common stock for interest paid-in-kind		$ 7,206		1,425,465		1,432,671
Issuance of common stock for interest paid in kind, shares		720,610
Stock issued with debt		$ 1,200		111,677		112,877
Stock issued with debt, shares		120,000
Warrants issued with debt			906,188			906,188
Net loss					(4,745,171)	(4,745,171)
Beneficial conversion feature on debt				513,070		513,070
Ending balance, value at Jun. 30, 2021	$ 1,093	$ 62,608	30,911,495	55,317,862	(108,595,951)	(22,302,893)
Ending balance, shares at Jun. 30, 2021	109,312	6,260,884
Stock-based compensation				95,248		95,248
Series AA Preferred Stock dividend					(432,149)	(432,149)
Issuance of common stock for services		$ 1,358		339,642		341,000
Issuance of common stock for services, shares		135,800
Conversion of debt and interest for common stock		$ 8,963		2,231,777		2,240,740
Conversion of debt and interest for common stock, shares		896,296
Issuance of common stock for interest paid-in-kind		$ 7,883		2,146,064		2,153,947
Issuance of common stock for interest paid in kind, shares		788,200
Stock issued with debt		$ 2,276		436,045		438,321
Stock issued with debt, shares		227,650
Warrants issued with debt			334,704			334,704
Net loss					(4,951,113)	(4,951,113)
Beneficial conversion feature on debt				664,681		664,681
Series AA Preferred Stock offering	$ 4		459,246	455,750		915,000
Series AA Preferred Stock offering, shares	366
Beneficial conversion option on convertible preferred stock				815,914		815,914
Deemed dividend on convertible preferred stock				(815,914)		(815,914)
Issuance of common stock for non-cash warrant exercise		$ 363	(343,201)	342,838
Issuance of common stock for non-cash warrant exercise, shares		36,290
Series AA Preferred Stock issued for settlement of liabilities	$ 2		245,635	277,617		523,254
Series AA Preferred Stock issued for settlement of liabilities, shares	200
Ending balance, value at Sep. 30, 2021	$ 1,099	$ 83,451	31,607,879	62,307,524	(113,979,213)	(19,979,260)
Ending balance, shares at Sep. 30, 2021	109,878	8,345,120
Beginning balance, value at Dec. 31, 2021	$ 1,099	$ 91,206	31,715,154	64,261,048	(118,277,468)	(22,208,961)
Beginning balance, shares at Dec. 31, 2021	109,878	9,120,526
Early adoption of ASU 2020-06				(2,728,243)	2,255,216	(473,027)
Stock-based compensation				64,483		64,483
Series AA Preferred Stock dividend					(432,149)	(432,149)
Issuance of common stock for services		$ 370		77,330		77,700
Issuance of common stock for services, shares		37,000
Issuance of common stock warrants for services			39,761			39,761
Warrants issued for debt extension			132,537			132,537
Common stock issued for debt extension		$ 2,145		470,755		472,900
Common stock issued for debt extension, shares		214,500
Conversion of debt and interest for common stock		$ 1,402		349,098		350,500
Conversion of debt and interest for common stock, shares		140,200
Issuance of common stock for dividends paid-in-kind		$ 318		63,938		64,256
Issuance of common stock for dividends paid-in-kind, shares		31,810
Issuance of common stock for interest paid-in-kind		$ 5,581		1,167,877		1,173,458
Issuance of common stock for interest paid in kind, shares		558,100
Stock issued with debt		$ 920		141,560		142,480
Stock issued with debt, shares		92,000
Warrants issued with debt			87,436			87,436
Net loss					(4,239,685)	(4,239,685)
Ending balance, value at Mar. 31, 2022	$ 1,099	$ 101,942	31,974,888	63,867,846	(120,694,086)	(24,748,311)
Ending balance, shares at Mar. 31, 2022	109,878	10,194,136
Beginning balance, value at Dec. 31, 2021	$ 1,099	$ 91,206	$ 31,715,154	64,261,048	(118,277,468)	(22,208,961)
Beginning balance, shares at Dec. 31, 2021	109,878	9,120,526
Common stock issued for debt extension, shares			277,500
Net loss						$ (11,618,260)
Stock option exercise, shares						25,279
Ending balance, value at Sep. 30, 2022	$ 1,098	$ 122,207	$ 31,995,762	67,041,489	(128,936,078)	$ (29,775,522)
Ending balance, shares at Sep. 30, 2022	109,874	12,220,611
Beginning balance, value at Mar. 31, 2022	$ 1,099	$ 101,942	31,974,888	63,867,846	(120,694,086)	(24,748,311)
Beginning balance, shares at Mar. 31, 2022	109,878	10,194,136
Stock-based compensation				32,074		32,074
Series AA Preferred Stock dividend					(431,708)	(431,708)
Issuance of common stock for services		$ 400		67,400		67,800
Issuance of common stock for services, shares		40,000
Common stock issued for debt extension		$ 1,064		190,239		191,303
Common stock issued for debt extension, shares		106,400
Issuance of common stock for dividends paid-in-kind		$ 865		150,156		151,021
Issuance of common stock for dividends paid-in-kind, shares		86,464
Issuance of common stock for interest paid-in-kind		$ 2,245		386,270		388,515
Issuance of common stock for interest paid in kind, shares		224,500
Stock issued with debt		$ 220		35,628		35,848
Stock issued with debt, shares		22,000
Net loss					(2,916,338)	(2,916,338)
Stock option exercise		$ 253		17,190		17,443
Stock option exercise, shares		25,279
Conversion of preferred stock for common stock	$ (1)	$ 44		(43)
Conversion of preferred stock for common stock, shares	(4)	4,400
Ending balance, value at Jun. 30, 2022	$ 1,098	$ 107,033	31,974,888	64,746,760	(124,042,132)	(27,212,353)
Ending balance, shares at Jun. 30, 2022	109,874	10,703,179
Stock-based compensation				32,427		32,427
Series AA Preferred Stock dividend					(431,709)	(431,709)
Issuance of common stock for services		$ 1,135		166,240		167,375
Issuance of common stock for services, shares		113,500
Common stock issued for debt extension		$ 7,079		1,043,396		1,050,475
Common stock issued for debt extension, shares		707,900
Issuance of common stock for dividends paid-in-kind		$ 520		90,536		91,056
Issuance of common stock for dividends paid-in-kind, shares		52,032
Issuance of common stock for interest paid-in-kind		$ 3,895		630,410		634,305
Issuance of common stock for interest paid in kind, shares		389,500
Stock issued with debt		$ 2,545		331,720		334,265
Stock issued with debt, shares		254,500
Warrants issued with debt			6,140			6,140
Net loss					(4,462,237)	(4,462,237)
Warrants issued for services			14,734			14,734
Ending balance, value at Sep. 30, 2022	$ 1,098	$ 122,207	$ 31,995,762	$ 67,041,489	$ (128,936,078)	$ (29,775,522)
Ending balance, shares at Sep. 30, 2022	109,874	12,220,611

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure BioSciences, Inc. (OTCQB: PBIO The Company was founded on the belief that its PCT Platform had the potential to significantly increase the quality of sample preparation in both research and clinical settings. Although this premise has been proven true, and although PBI has been successful in installing its PCT Platform in the laboratories of key opinion leaders worldwide, the Company now believes – based on market feedback – that the commercial potential for its UST Platform far exceeds the potential of the PCT Platform. Consequently, in January 2022, PBI made the critical decision to immediately shift its primary business focus from PCT to its innovative UST Platform. The UST Platform The BaroFold Platform The PCT Platform

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced losses from operations and negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of September 30, 2022, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising debt and equity capital in the past and as described in Notes 5 and 6. In addition we raised debt and equity capital after September 30, 2022 as described in Note 7. We have financing efforts in place to continue to raise cash through debt and equity offerings. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. These financial statements do not include any adjustments that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3) Summary of Significant Accounting Policies Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2021. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022. Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216 Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue Primary geographical markets 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Primary geographical markets 2022 2021 2022 2021 North America $ 138 $ 351 $ 709 $ 1,036 Europe 13 57 61 244 Asia (7 ) 110 352 407 $ 144 $ 518 $ 1,122 $ 1,687 Major products/services lines 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Major products/services lines 2022 2021 2022 2021 Hardware $ 1 $ 276 $ 532 $ 989 Consumables 49 45 165 191 Contract research services - 100 125 242 Sample preparation accessories 41 39 93 108 Technical support/extended service contracts 41 26 94 84 Agrochem Products 10 17 93 17 Shipping and handling 2 11 20 46 Other - 4 - 10 Revenue $ 144 $ 518 $ 1,122 $ 1,687 1 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Timing of revenue recognition 2022 2021 2022 2021 Products transferred at a point in time $ 103 $ 392 $ 903 $ 1,361 Services transferred over time 41 126 219 326 Revenue $ 144 $ 518 $ 1,122 $ 1,687 Contract balances Schedule of Contract Balances 1 2 In thousands of US dollars ($) September 30, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 166 $ 155 Contract liabilities (deferred revenue) 127 41 Transaction price allocated to the remaining performance obligations. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 32 $ 95 $ 127 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Top Five Customers 42 % 56 % 31 % 42 % Federal Agencies 4 % 3 % 1 % 6 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. September 30, December 31, Top Five Customers 84 % 82 % Federal Agencies 0 % 5 % Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers, who was in fact one of the largest life science instrument manufacturers in the U.S. We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during the quarter ending September 30, 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments. Investment in Equity Securities As of September 30, 2022, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”. ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of September 30, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 51,929 8,047 Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2022 and 2021: Schedule of Computation of Loss Per Share 2022 2021 2022 2021 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (4,893,946 ) $ (6,199,176 ) $ (12,913,826 ) $ (18,387,204 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 11,131,742 7,561,728 10,429,817 6,083,017 Loss per common share – basic and diluted $ (0.44 ) $ (0.82 ) $ (1.24 ) $ (3.02 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 As of September 30, 2022 2021 Stock options 1,307,822 1,342,490 Convertible debt 6,471,034 5,330,318 Common stock warrants 16,293,768 16,265,570 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,645,000 8,649,000 Total potentially dilutive shares 33,217,416 32,087,170 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option and Warrant Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5 The Company recognized stock-based compensation expense of $ 32,427 95,248 128,984 219,943 Schedule of Stock Based Compensation Expense 2022 2021 2022 2021 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of sales $ 2,184 $ 8,664 $ 8,694 $ 18,824 Research and development 9,499 43,031 37,803 95,384 Selling and marketing 4,583 7,168 18,166 17,650 General and administrative 16,161 36,385 64,321 88,085 Total stock-based compensation expense $ 32,427 $ 95,248 $ 128,984 $ 219,943 Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at September 30, 2022 using: September 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 51,929 $ 51,929 - - Total Financial Assets $ 51,929 $ 51,929 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4) Commitments and Contingencies Operating Leases The Company accounts for its leases under ASC 842. The Company has elected to apply the short-term lease exception to leases of one year or less. Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $ 6,950 December 31, 2022 We extended our lease for our space in Medford, MA (the “Medford Lease”) from December 30, 2020 to December 30, 2023 7,282 The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term The Company accounted for the lease extension of our Medford Lease as a lease modification under ASC 842. At the effective date of modification, the Company recorded an adjustment to the right-of-use asset and lease liability in the amount of $ 221,432 12 On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term The Company accounted for the Sparks Lease as an operating lease under ASC 842. Upon the commencement of the lease, the Company recorded a right-of-use asset and lease liability in the amount of $ 239,327 12 Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 57,971 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 390,410 Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle 1,200 2,000 3,000 4,000 5,000 Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $ 1,400 2,000 60,000 60,000 65,100 44,600 Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, and Lazarev, executive officers of the Company, are entitled to receive a severance payment if terminated by the Company without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of their termination upon a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the control change.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	5) Convertible Debt and Other Debt Convertible Debt On various dates during the nine months ended September 30, 2022, the Company issued convertible notes for a total of $ 3,921,617 1 12 12 15 2.50 606,169 The specific terms of the convertible notes and outstanding balances as of September 30, 2022 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 (1)(2) 12 months $ 380,000 $ 98,544 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 (1)(4) 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 - June 4, 2019 (1)(2) 9 months $ 500,000 $ 302,484 - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 (1) (2) 12 months $ 115,000 $ 115,000 - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 (1) (2) 12 months $ 78,750 $ 78,750 - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 (1) (2) 12 months $ 78,750 $ 78,750 - 4 % $ 2.50 $ 3,750 - November 15,2019 (1) 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2,2020 (1) 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24,2020 (1) 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 (1) 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 (1) 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19,2020 (1) 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11,2020 (1) 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 (1) 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 (1) 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 (1) 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17,2020 (1) 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 - $ 96,208 April 30,2020 (1) 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 (1) 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18,2020 (1) 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 (1) 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12,2020 (1) 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 (1) 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 (1) 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 (1) 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 (1) 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 (1) (5) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 (1) 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 (1) 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 (1) (5) 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 (1) 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 December 3, 2020 (1) 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 (1) (5) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 (1) 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 (1) 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 - $ 36,431 May 6, 2021 (1) 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 (1) 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 (1) 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 - $ 773,802 August 4, 2022 (13) 12 months $ 50,000 $ 50,000 $ 1,500 12 % (14 ) - $ 7,948 August 31, 2022 (13) 6 months $ 700,000 $ 700,000 $ 84,000 12 % (6 ) - - July 3, 2021 (1) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 July 1,2022 (13) 6 months $ 260,000 $ 185,000 $ 10,000 12 % (15 ) $ 2,000 - February 4, 2022 (1)(13) 8 months $ 500,000 $ 500,000 $ 30,000 12 % (11 ) - - May 13, 2022 (11)(13) 7 months $ 500,000 $ 500,000 $ 25,000 12 % (11 ) - - January 19,2022 (1) (13) 6 months $ 52,000 $ 52,000 $ 2,000 12 % $ 2.50 $ 2,000 - September 16, 2022 (3)(13) 1 month $ 352,188 $ 352,188 $ 45,938 15 % (8 ) - - September 26, 2022 (1)(3)(13) 1 month $ 140,875 $ 140,875 $ 18,375 15 % (8 ) - - August 31, 2021 (1) 12 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 May 8, 2022 8 months $ 65,000 $ 65,000 $ 3,000 12 % (7 ) - - September 10, 2021 (1) 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) - $ 43,520 September 15, 2021 (1) 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) - $ 108,801 September 16, 2021 (1) 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) - $ 112,337 September 24, 2021 (1) 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) - $ 61,876 September 15, 2021 (1) 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 - October 21, 2021 (1)(5) 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 (1)(5) 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 - $ 96,991 March 29,2022 8 months $ 112,000 $ (8,573 ) $ 13,000 12 % (12 ) - - February 9,2022 12 months $ 88,987 $ 35,737 $ 10,237 12 % (10 ) - - March 30,2022 12 months $ 100,000 $ 100,000 $ 5,000 12 % $ 2.50 - $ 19,614 April 19,2022 12 months $ 95,000 $ 95,000 - 12 % (12 ) - $ 16,234 May 23,2022 8 months $ 950,000 $ 950,000 $ 57,000 12 % $ 2.50 $ 22,333 - July 15, 2022 12 months $ 22,000 $ 22,000 $ 880 12 % $ 2.50 - $ 6,286 August 3, 2022 12 months $ 25,000 $ 25,000 $ 980 12 % $ 2.50 - $ 6,412 August 10, 2022 12 months $ 196,319 $ 196,319 $ 22,585 12 % (10 ) - - August 11, 2022 12 months $ 50,000 $ 50,000 $ 2,000 12 % (16 ) - - August 17, 2022 12 months $ 50,000 $ 50,000 $ 2,000 12 % (15 ) - $ 7,149 August 24, 2022 12 months $ 200,000 $ 200,000 $ 14,000 15 % (15 ) - - September 7, 2022 12 months $ 50,000 $ 50,000 $ 2,000 12 % (14 ) - 9,845 September 8, 2022 12 months $ 87,500 $ 87,500 $ 11,375 12 % (12 ) - $ 22,430 September 16, 2022 12 months $ 113,000 $ 113,000 - 12 % (17 ) - $ 25,651 September 9, 2022 10 months $ 175,000 $ 175,000 $ 22,750 12 % (12 ) - - September 26, 2022 (1) 1 month $ 26,250 $ 26,250 - 0 % (15 ) - - September 28, 2022 12 months $ 52,000 $ 52,000 - 12 % (14 ) - $ 8,420 September 28, 2022 9 months $ 262,500 $ 262,500 $ 12,500 12 % (18 ) - $ 50,005 $ 17,142,974 $ 1,794,220 $ 984,083 $ 8,496,019 Less remaining debt discount $ 434,313 Total convertible debt $ 16,708,661 Notes: (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lenders have entered into Standstill and Forbearance Agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and interest rate is 40.9 (4) During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion (7) Notes are convertible before maturity at $ 2.50 (8) Notes can be converted at the lesser of $ 2.5 25 35 (9) Conversion price of this note is $ 2.50 25 25 (10) Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion. (11) Loans can be voluntarily converted before maturity at $ 2.50 2.50 10 (12) Notes are convertible at $ 2.50 75 (13) During the nine months ended September 30, 2022, the Company extended 10 loans totaling $ 1,700,000 2,909,561 759,900 (14) These notes can be voluntary converted at lower of 1) $ 2.50 2.50 (15) These notes can be voluntary converted at lower of 1) $ 2.50 2.50 (16) Conversion price is lower of (i) $ 2.50 (17) Conversion price is $ 2.50 (18) Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50 As of September 30, 2022, one lender holds approximately $ 9.4 17.1 For the nine months ended September 30, 2022, the Company recognized amortization expense related to the debt discounts indicated above of $ 1,728,846 . The unamortized debt discounts as of September 30, 2022 related to the convertible debentures and other convertible notes amounted to $ 434,313 Standstill and Forbearance Agreements In recent years, the Company entered into Standstill and Forbearance Agreements with lenders who hold variable-rate convertible notes. Pursuant to these agreements the lenders agreed to not convert any portion of their notes into shares of common stock at a variable rate. The Company and two lenders ($ 673,528 In connection to these agreements, the Company incurred interest, penalties, and fees of approximately $ 202,058 606,158 Convertible Loan Modifications and Extinguishments We refinanced certain convertible loans during the nine months ended September 30, 2022 at substantially the same terms for extensions ranging over a period of one to twelve months. We amortized any remaining unamortized debt discount as of the modification date over the remaining, extended term of the new loans. We applied ASC 470 of modification accounting to the debt instruments which were modified during the quarter or those settled with new notes issued concurrently for the same amounts but different maturity dates. The terms such as the interest rate, prepayment penalties, and default rates will be the same over the new extensions. According to ASC 470, an exchange of debt instruments between or a modification of a debt instrument by a debtor and a creditor in a nontroubled debt situation is deemed to have been accomplished with debt instruments that are substantially different if the present value of the cash flows under the terms of the new debt instrument is at least 10 percent different from the present value of the remaining cash flows under the terms of the original instrument. If the terms of a debt instrument are changed or modified and the cash flow effect on a present value basis is less than 10 percent, the debt instruments are not considered to be substantially different and will be accounted for as modifications. The cash flows of new debt exceeded 10 1,809,249 by calculating the difference of the fair value of the new debt and the carrying value of the old debt. Other Debt Other debt consists of non-convertible debt and Merchant agreements. The following is a detail of the non-convertible debt: Schedule of Non Convertible Debt Principal Balance Note Original Term Inception September December Interest Rate Security Accredited investor 1 9 3/21/17 $ 170,000 $ 170,000 10 % Unsecured Accredited investor 2 13 9/19/19 & 2/28/20 691,500 691,500 7.5 % Unsecured (1) On Deck Capital 12 4/29/22 29,807 - 2.5 % (2) Unsecured Totals $ 891,307 $ 861,500 (1) As of September 30, 2022 the Company owes $ 691,500 100,000 3 3.50 (2) Rate is per month. The following is a detail of the Merchant agreements debt: We have signed various Merchant Agreements which are secured by second position rights to all customer receipts until the loan has been repaid in full and subject to interest rates of 2.8 9.1 The following table shows our Merchant Agreements as of September 30, 2022: Schedule of Merchant Agreements Issue Date Purchase Price Purchase Amount Outstanding Balance Payment Frequency Payment Rate Deferred Finance Fees 12/21/21 $ 400,000 $ 520,000 $ 65,126 Weekly $ 11,305 $ 6,000 5/11/22 $ 225,000 $ 308,250 $ 79,562 Weekly $ 11,009 - 6/28/22 $ 250,000 $ 337,250 $ 125,575 Daily $ 2,595 - 7/21/22 $ 180,000 $ 242,820 $ 114,081 Daily $ 1,868 - 8/8/22 $ 140,000 $ 190,260 $ 96,645 Daily $ 1,586 - 9/21/22 $ 190,000 $ 256,310 $ 183,479 Daily $ 1,972 - $ 1,385,000 $ 1,854,890 $ 664,468 The following table shows our Merchant Agreements as of December 31, 2021: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly $ 11,305 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily $ 1,279 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500 We have accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid each day. Related Party Debt Schedule of Related Party Debt Principal Balance Note September 30, 2022 December 31, 2021 Interest rate Security Candy Schumacher $ 70,400 $ - 12 % Unsecured Jeff Peterson 222,200 - 10 % (1) Unsecured Richard Schumacher 165,550 - 12 % Unsecured Accredited investor 3 110,000 - 12 % Unsecured Accredited investor 4 16,500 $ - 12 % Unsecured Totals $ 584,650 $ - Unamortized debt discount 19,149 - Total current notes due $ 565,501 $ - (1) Rate is per month. The related parties’ notes are due upon demand, 10 12 120 2.50 844,250 259,600 Long term debt The Company entered into a COVID-19 government loan in 2020, the Economic Injury Disaster Loan (or “EIDL”). The Company’s EIDL loan, $ 150,000 3.75 731 30

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Deficit	6) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $ .01 . Of the 1,000,000 shares of preferred stock, the following is outstanding: Schedule of Preferred Stock Outstanding September 30, 2022 December 31, 2021 Series D Convertible Preferred Stock, $ .01 par value; 850 shares authorized; 300 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively (Liquidation value of $ 300,000 ) 3 3 Series G Convertible Preferred Stock, $ .01 par value; 240,000 shares authorized; 80,570 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 806 806 Series H Convertible Preferred Stock, $ .01 par value; 10,000 shares authorized; 10,000 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 100 100 Series J Convertible Preferred Stock, $ .01 par value; 6,250 shares authorized; 3,458 and 3,458 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 35 35 Series K Convertible Preferred Stock, $ .01 par value; 15,000 shares authorized; 6,880 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 68 68 Series AA Convertible Preferred Stock, $ .01 par value; 10,000 shares authorized; 8,645 and 8,649 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 86 87 Series H2 Convertible Preferred Stock, $ .01 par value; 21 shares authorized; 21 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 1,098 $ 1,099 Stock Options and Warrants At the Company’s December 30, 2021 Special Meeting, the shareholder’s approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to which 3,000,000 1,307,822 As of September 30, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 43,971 0.70 1.30 751,466 The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Weighted Shares price Shares price Shares Total Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 277,500 3.50 277,500 Exercised (25,279 ) 0.69 - - (25,279 ) Expired/forfeited - - (190,840 ) $ 3.50 (190,840 ) Balance outstanding, September 30, 2022 1,307,822 $ 0.72 16,293,768 $ 3.50 17,601,590 17,533,679 As of September 30, 2022, the 1,307,822 $0.72 6.96 1,239,911 Common Stock and Warrant Issuances As profiled in the following table, for five loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Loan Issuance Date Loan Principal % of Loan Principal Issuable Defined Date Shares Issuable Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 4 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly Loan 5 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly For the three-month and nine-month period ended September 30, 2022, the Company is obligated to issue 389,500 1,172,100 634,305 2,196,278 During the nine months ended September 30, 2022, the Company issued a total of 3,100,085 ● 25,279 17,443 ● 190,500 312,875 ● 1,028,800 1,714,678 ● 140,200 350,500 ● 4,400 ● 1,172,100 2,196,278 ● 368,500 512,593 ● 170,306 306,333 During the nine months ended September 30, 2021, we issued a total of 4,176,796 ● 2,431,182 5.6 ● 248,200 579,512 ● 1,035,996 2,589,990 ● 21,411 0.69 ● 56,067 114,298 ● 347,650 551,198 ● 36,290 During the nine months ended September 30, 2022, the Company issued a total of 277,500 280,608 3.50 3 5 ● 120,000 ● 100,000 ● 57,500 During the nine months ended September 30, 2021, we issued 1,558,266 three five 3.50 5.00 2.0 In this period, we also issued 200 200,100 five year 3.50 245,635 23,004 406 1,000 0.01 1,015,000 406,000 3.50

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	7) Subsequent Events From October 1, 2022 through November 18, 2022 the Company borrowed $ 10 4,500 due upon demand, 10% OID and 10 580,000 5,835 for 130 to 140 days 1,011,960 loan term are from 2 to 12 months; interest rate from 0% to 24%, convertible into the Company’s common stock at a fixed rate of $2.50 per share or at a variable conversion rate upon an event of default 150,000 352,188 one month 146,542 On October 5, 2022, a convertible note converted a $ 98,544 5,751 41,718

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim financial statements of Pressure BioSciences, Inc. and its consolidated subsidiaries (collectively, the “Company”) included herein have been prepared by the Company in accordance with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission. Under these rules and regulations, some information and footnote disclosures normally included in financial statements prepared under accounting principles generally accepted in the United States of America have been shortened or omitted. Management believes that all adjustments necessary for a fair statement of the financial position and the results of operations for the periods shown have been made. All adjustments are normal and recurring. These financial statements should be read together with the Company’s audited financial statements included in its Form 10-K for the fiscal year ended December 31, 2021. Operating results for the nine months ended September 30, 2022 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2022.
Use of Estimates	Use of Estimates The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes the beneficial conversion separation model for convertible debt. As a result, after adopting the guidance, entities will no longer account for beneficial conversion features in equity. The guidance is effective for public business entities, other than small reporting company’s financial statements starting January 1, 2022, with early adoption permitted. The Company is a small reporting company and early adopted the new guidance on January 1, 2022 using the modified retrospective approach and recorded a cumulative effect of adoption equal to a $ 2,728,243 2,255,216
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly owned subsidiaries PBI BioSeq, Inc. and PBI Agrochem, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, ASC 340-40, Other Assets and Deferred Costs—Contracts with Customers We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are in included in cost of revenues as consistent with treatment in prior periods. Our current Barocycler® instruments require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request, and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers® that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Our sales arrangements do not provide our customers with a right of return. Any shipping costs billed to customers are recognized as revenue. The majority of our instrument and consumable contracts contain pricing that is based on the market price for the product at the time of delivery. Our obligations to deliver product volumes are typically satisfied and revenue is recognized when control of the product transfers to our customers. Concurrent with the transfer of control, we typically receive the right to payment for the shipped product and the customer has significant risks and rewards of ownership of the product. Payment terms require customers to pay shortly after delivery and do not contain significant financing components. Revenue from scientific services customers is recognized upon completion of each stage of service as defined in service agreements. We apply ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. We recognize revenue for non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for lease agreements of our instruments in accordance with ASC 842, Leases. We record revenue over the life of the lease term, and we record depreciation expense on a straight-line basis over the thirty-six-month estimated useful life of the Barocycler® instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our accompanying consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Deferred revenue represents amounts received from service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. Revenue from service contracts is recorded ratably over the length of the contract. Disaggregation of revenue In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue Primary geographical markets 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Primary geographical markets 2022 2021 2022 2021 North America $ 138 $ 351 $ 709 $ 1,036 Europe 13 57 61 244 Asia (7 ) 110 352 407 $ 144 $ 518 $ 1,122 $ 1,687 Major products/services lines 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Major products/services lines 2022 2021 2022 2021 Hardware $ 1 $ 276 $ 532 $ 989 Consumables 49 45 165 191 Contract research services - 100 125 242 Sample preparation accessories 41 39 93 108 Technical support/extended service contracts 41 26 94 84 Agrochem Products 10 17 93 17 Shipping and handling 2 11 20 46 Other - 4 - 10 Revenue $ 144 $ 518 $ 1,122 $ 1,687 1 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Timing of revenue recognition 2022 2021 2022 2021 Products transferred at a point in time $ 103 $ 392 $ 903 $ 1,361 Services transferred over time 41 126 219 326 Revenue $ 144 $ 518 $ 1,122 $ 1,687 Contract balances Schedule of Contract Balances 1 2 In thousands of US dollars ($) September 30, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 166 $ 155 Contract liabilities (deferred revenue) 127 41 Transaction price allocated to the remaining performance obligations. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 32 $ 95 $ 127 All consideration from contracts with customers is included in the amounts presented above. Contract Costs The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. The costs to obtain a contract are recorded immediately in the period when the revenue is recognized either upon shipment or installation. The costs to obtain a service contract are considered immaterial when spread over the life of the contract so the Company records the costs immediately upon billing.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Top Five Customers 42 % 56 % 31 % 42 % Federal Agencies 4 % 3 % 1 % 6 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. September 30, December 31, Top Five Customers 84 % 82 % Federal Agencies 0 % 5 %
Product Supply	Product Supply In recent years we utilized a contract assembler for our Barocycler® 2320EXT. They provided us with precision manufacturing services that included management support services to meet our specific application and operational requirements. Among the services provided to us were: ● CNC Machining ● Contract Assembly & Kitting ● Component and Subassembly Design ● Inventory Management ● ISO certification Beginning in July 2021, we brought the assembly of our Barocycler 2320EXT instruments in-house. This became necessary when our independent contract assembler (CBM Industries) informed us that they were about to need 100% of their assembly space for one of their customers, who was in fact one of the largest life science instrument manufacturers in the U.S. We worked with our notified body to gain approval to use both the CE and CSA marks on the instrument, which we received during the quarter ending September 30, 2021. Until further notice, we expect to continue to assemble our Barocycler 2320EXT instrument at our South Easton, MA location. We currently manufacture and assemble the Barocycler®, HUB440, HUB880, the SHREDDER SG3, and most of our consumables at our South Easton, MA facility. We will regularly reassess the tradeoffs between in-house assembly versus the benefits of outsourced relationships for of the entire Barocycler® product line, and future instruments.
Investment in Equity Securities	Investment in Equity Securities As of September 30, 2022, we held 100,250 We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”. ASC 320 requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in net income. As of September 30, 2022, our consolidated balance sheet reflected the fair value, determined on a recurring basis based on Level 1 inputs of our investment in Nexity, to be $ 51,929 8,047
Computation of Loss per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2022 and 2021: Schedule of Computation of Loss Per Share 2022 2021 2022 2021 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (4,893,946 ) $ (6,199,176 ) $ (12,913,826 ) $ (18,387,204 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 11,131,742 7,561,728 10,429,817 6,083,017 Loss per common share – basic and diluted $ (0.44 ) $ (0.82 ) $ (1.24 ) $ (3.02 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H and H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock, and Series AA Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 As of September 30, 2022 2021 Stock options 1,307,822 1,342,490 Convertible debt 6,471,034 5,330,318 Common stock warrants 16,293,768 16,265,570 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,645,000 8,649,000 Total potentially dilutive shares 33,217,416 32,087,170
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option and Warrant Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5 The Company recognized stock-based compensation expense of $ 32,427 95,248 128,984 219,943 Schedule of Stock Based Compensation Expense 2022 2021 2022 2021 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of sales $ 2,184 $ 8,664 $ 8,694 $ 18,824 Research and development 9,499 43,031 37,803 95,384 Selling and marketing 4,583 7,168 18,166 17,650 General and administrative 16,161 36,385 64,321 88,085 Total stock-based compensation expense $ 32,427 $ 95,248 $ 128,984 $ 219,943
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt approximate their fair value. The carrying amount of long-term debt approximates fair value due to interest rates that approximate prevailing market rates.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. A slight change in an unobservable input like volatility could have a significant impact on fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at September 30, 2022 using: September 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 51,929 $ 51,929 - - Total Financial Assets $ 51,929 $ 51,929 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition. Schedule of Disaggregation of Revenue Primary geographical markets 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Primary geographical markets 2022 2021 2022 2021 North America $ 138 $ 351 $ 709 $ 1,036 Europe 13 57 61 244 Asia (7 ) 110 352 407 $ 144 $ 518 $ 1,122 $ 1,687 Major products/services lines 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Major products/services lines 2022 2021 2022 2021 Hardware $ 1 $ 276 $ 532 $ 989 Consumables 49 45 165 191 Contract research services - 100 125 242 Sample preparation accessories 41 39 93 108 Technical support/extended service contracts 41 26 94 84 Agrochem Products 10 17 93 17 Shipping and handling 2 11 20 46 Other - 4 - 10 Revenue $ 144 $ 518 $ 1,122 $ 1,687 1 2022 2021 2022 2021 In thousands of US dollars ($) Three Months Ended Nine Months Ended Timing of revenue recognition 2022 2021 2022 2021 Products transferred at a point in time $ 103 $ 392 $ 903 $ 1,361 Services transferred over time 41 126 219 326 Revenue $ 144 $ 518 $ 1,122 $ 1,687
Schedule of Contract Balances	Contract balances Schedule of Contract Balances 1 2 In thousands of US dollars ($) September 30, 2022 December 31, 2021 Receivables, which are included in ‘Accounts Receivable’ $ 166 $ 155 Contract liabilities (deferred revenue) 127 41
Schedule of Future Related to Performance Obligations	Schedule of Future Related to Performance Obligations In thousands of US dollars ($) 2022 2023 Total Extended warranty service $ 32 $ 95 $ 127
Schedule of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three and nine months ended September 30, 2022 and 2021. Schedule of Customer Concentration Risk Percentage For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Top Five Customers 42 % 56 % 31 % 42 % Federal Agencies 4 % 3 % 1 % 6 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable. September 30, December 31, Top Five Customers 84 % 82 % Federal Agencies 0 % 5 %
Schedule of Computation of Loss Per Share	The following table illustrates our computation of loss per share for the three and nine months ended September 30, 2022 and 2021: Schedule of Computation of Loss Per Share 2022 2021 2022 2021 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common stockholders $ (4,893,946 ) $ (6,199,176 ) $ (12,913,826 ) $ (18,387,204 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 11,131,742 7,561,728 10,429,817 6,083,017 Loss per common share – basic and diluted $ (0.44 ) $ (0.82 ) $ (1.24 ) $ (3.02 )
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 As of September 30, 2022 2021 Stock options 1,307,822 1,342,490 Convertible debt 6,471,034 5,330,318 Common stock warrants 16,293,768 16,265,570 Convertible preferred stock: Series D Convertible Preferred Stock 25,000 25,000 Series G Convertible Preferred Stock 26,857 26,857 Series H Convertible Preferred Stock 33,334 33,334 Series H2 Convertible Preferred Stock 70,000 70,000 Series J Convertible Preferred Stock 115,267 115,267 Series K Convertible Preferred Stock 229,334 229,334 Series AA Convertible Preferred Stock 8,645,000 8,649,000 Total potentially dilutive shares 33,217,416 32,087,170
Schedule of Stock Based Compensation Expense	Schedule of Stock Based Compensation Expense 2022 2021 2022 2021 For the Three Months Ended For the Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Cost of sales $ 2,184 $ 8,664 $ 8,694 $ 18,824 Research and development 9,499 43,031 37,803 95,384 Selling and marketing 4,583 7,168 18,166 17,650 General and administrative 16,161 36,385 64,321 88,085 Total stock-based compensation expense $ 32,427 $ 95,248 $ 128,984 $ 219,943
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2022: Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis Fair value measurements at September 30, 2022 using: September 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities $ 51,929 $ 51,929 - - Total Financial Assets $ 51,929 $ 51,929 $ - $ - The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2021: Fair value measurements at December 31, 2021 using: December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Equity Securities 59,976 59,976 - - Total Financial Assets $ 59,976 $ 59,976 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2022: Schedule of Future Minimum Rental Payments Required Under Operating Leases 2022 $ 57,971 2023 149,299 2024 64,393 2025 66,969 2026 51,778 Thereafter - Total $ 390,410

Convertible Debt and Other De_2

Convertible Debt and Other Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible notes and outstanding balances as of September 30, 2022 are listed in the tables below. Schedule of Convertible Debts and Outstanding Balances Inception Date Term Loan Amount Outstanding balance with OID Original Issue Discount (OID) Interest Rate Conversion Price Deferred Finance Fees Discount for conversion feature and warrants/shares May 17, 2018 (1)(2) 12 months $ 380,000 $ 98,544 $ 15,200 8 % $ 2.50 $ 15,200 $ 332,407 January 3, 2019 (1)(4) 6 months $ 50,000 $ 50,000 $ 2,500 24 % $ 7.50 $ 2,500 - June 4, 2019 (1)(2) 9 months $ 500,000 $ 302,484 - 8 % $ 2.50 $ 40,500 $ 70,631 July 19, 2019 (1) (2) 12 months $ 115,000 $ 115,000 - 4 % $ 2.50 $ 5,750 $ 15,460 September 27,2019 (1) (2) 12 months $ 78,750 $ 78,750 - 4 % $ 2.50 $ 3,750 $ 13,759 October 24, 2019 (1) (2) 12 months $ 78,750 $ 78,750 - 4 % $ 2.50 $ 3,750 - November 15,2019 (1) 12 months $ 385,000 $ 320,000 $ 35,000 10 % $ 2.50 $ 35,000 $ 90,917 January 2,2020 (1) 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 91,606 January 24,2020 (1) 12 months $ 247,500 $ 247,500 $ 22,500 10 % $ 2.50 $ 22,500 $ 89,707 January 29, 2020 (1) 12 months $ 363,000 $ 363,000 $ 33,000 10 % $ 2.50 $ 33,000 $ 297,000 February 12, 2020 (1) 12 months $ 275,000 $ 275,000 $ 25,000 10 % $ 2.50 $ 25,000 $ 225,000 February 19,2020 (1) 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 135,000 March 11,2020 (1) 12 months $ 330,000 $ 330,000 $ 30,000 10 % $ 2.50 $ 30,000 $ 232,810 March 13, 2020 (1) 12 months $ 165,000 $ 165,000 $ 15,000 10 % $ 2.50 $ 15,000 $ 60,705 March 26, 2020 (1) 12 months $ 111,100 $ 111,100 $ 10,100 10 % $ 2.50 $ 10,100 $ 90,900 April 8, 2020 (1) 12 months $ 276,100 $ 276,100 $ 25,100 10 % $ 2.50 $ 25,000 $ 221,654 April 17,2020 (1) 12 months $ 143,750 $ 143,750 $ 18,750 10 % $ 2.50 - $ 96,208 April 30,2020 (1) 12 months $ 546,250 $ 546,250 $ 71,250 10 % $ 2.50 $ 47,500 $ 427,500 May 6, 2020 (1) 12 months $ 460,000 $ 460,000 $ 60,000 10 % $ 2.50 $ 40,000 $ 360,000 May 18,2020 (1) 12 months $ 546,250 $ 221,250 $ 46,250 10 % $ 2.50 $ 35,500 $ 439,500 June 2, 2020 (1) 12 months $ 902,750 $ 652,750 $ 92,750 10 % $ 2.50 $ 58,900 $ 708,500 June 12,2020 (1) 12 months $ 57,500 $ 57,500 $ 7,500 10 % $ 2.50 $ 5,000 $ 45,000 June 22, 2020 (1) 12 months $ 138,000 $ 138,000 $ 18,000 10 % $ 2.50 $ 12,000 $ 108,000 July 7, 2020 (1) 12 months $ 586,500 $ 586,500 $ 76,500 10 % $ 2.50 $ 51,000 $ 400,234 July 17, 2020 (1) 12 months $ 362,250 $ 362,250 $ 47,250 10 % $ 2.50 $ 31,500 $ 185,698 July 29, 2020 (1) 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 241,245 July 21, 2020 (1) (5) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 24,875 August 14, 2020 (1) 12 months $ 762,450 $ 462,450 $ 69,450 10 % $ 2.50 $ 66,300 $ 580,124 September 10, 2020 (1) 12 months $ 391,000 $ 391,000 $ 51,000 10 % $ 2.50 $ 34,000 $ 231,043 September 21, 2020 (1) (5) 12 months $ 345,000 $ 345,000 $ 45,000 10 % $ 2.50 $ 30,000 $ 66,375 September 23, 2020 (1) 12 months $ 115,000 $ 15,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 20,500 December 3, 2020 (1) 12 months $ 299,000 $ 299,000 $ 39,000 10 % $ 2.50 $ 26,000 $ 197,882 October 22, 2020 (1) (5) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 18,875 February 17, 2021 (1) 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 180,000 March 23, 2021 (1) 12 months $ 55,000 $ 55,000 $ 5,000 10 % $ 2.50 - $ 36,431 May 6, 2021 (1) 12 months $ 402,500 $ 402,500 $ 52,500 10 % $ 2.50 $ 35,000 $ 312,551 June 17, 2021 (1) 12 months $ 230,000 $ 230,000 $ 30,000 10 % $ 2.50 $ 20,000 $ 144,760 June 25, 2021 (1) 12 months $ 977,500 $ 977,500 $ 127,500 10 % $ 2.50 - $ 773,802 August 4, 2022 (13) 12 months $ 50,000 $ 50,000 $ 1,500 12 % (14 ) - $ 7,948 August 31, 2022 (13) 6 months $ 700,000 $ 700,000 $ 84,000 12 % (6 ) - - July 3, 2021 (1) 12 months $ 115,000 $ 115,000 $ 15,000 10 % $ 2.50 $ 10,000 $ 90,000 July 1,2022 (13) 6 months $ 260,000 $ 185,000 $ 10,000 12 % (15 ) $ 2,000 - February 4, 2022 (1)(13) 8 months $ 500,000 $ 500,000 $ 30,000 12 % (11 ) - - May 13, 2022 (11)(13) 7 months $ 500,000 $ 500,000 $ 25,000 12 % (11 ) - - January 19,2022 (1) (13) 6 months $ 52,000 $ 52,000 $ 2,000 12 % $ 2.50 $ 2,000 - September 16, 2022 (3)(13) 1 month $ 352,188 $ 352,188 $ 45,938 15 % (8 ) - - September 26, 2022 (1)(3)(13) 1 month $ 140,875 $ 140,875 $ 18,375 15 % (8 ) - - August 31, 2021 (1) 12 months $ 189,750 $ 189,750 $ 24,750 10 % (9 ) $ 16,500 $ 148,500 May 8, 2022 8 months $ 65,000 $ 65,000 $ 3,000 12 % (7 ) - - September 10, 2021 (1) 8 months $ 100,000 $ 100,000 $ 4,000 12 % (7 ) - $ 43,520 September 15, 2021 (1) 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) - $ 108,801 September 16, 2021 (1) 6 months $ 250,000 $ 250,000 $ 12,500 12 % (7 ) - $ 112,337 September 24, 2021 (1) 8 months $ 125,000 $ 125,000 $ 6,250 12 % (7 ) - $ 61,876 September 15, 2021 (1) 6 months $ 250,000 $ 250,000 $ 37,500 12 % (7 ) $ 30,000 - October 21, 2021 (1)(5) 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 $ 16,500 $ 87,332 November 1, 2021 (1)(5) 12 months $ 189,750 $ 189,750 $ 24,750 12 % $ 2.50 - $ 96,991 March 29,2022 8 months $ 112,000 $ (8,573 ) $ 13,000 12 % (12 ) - - February 9,2022 12 months $ 88,987 $ 35,737 $ 10,237 12 % (10 ) - - March 30,2022 12 months $ 100,000 $ 100,000 $ 5,000 12 % $ 2.50 - $ 19,614 April 19,2022 12 months $ 95,000 $ 95,000 - 12 % (12 ) - $ 16,234 May 23,2022 8 months $ 950,000 $ 950,000 $ 57,000 12 % $ 2.50 $ 22,333 - July 15, 2022 12 months $ 22,000 $ 22,000 $ 880 12 % $ 2.50 - $ 6,286 August 3, 2022 12 months $ 25,000 $ 25,000 $ 980 12 % $ 2.50 - $ 6,412 August 10, 2022 12 months $ 196,319 $ 196,319 $ 22,585 12 % (10 ) - - August 11, 2022 12 months $ 50,000 $ 50,000 $ 2,000 12 % (16 ) - - August 17, 2022 12 months $ 50,000 $ 50,000 $ 2,000 12 % (15 ) - $ 7,149 August 24, 2022 12 months $ 200,000 $ 200,000 $ 14,000 15 % (15 ) - - September 7, 2022 12 months $ 50,000 $ 50,000 $ 2,000 12 % (14 ) - 9,845 September 8, 2022 12 months $ 87,500 $ 87,500 $ 11,375 12 % (12 ) - $ 22,430 September 16, 2022 12 months $ 113,000 $ 113,000 - 12 % (17 ) - $ 25,651 September 9, 2022 10 months $ 175,000 $ 175,000 $ 22,750 12 % (12 ) - - September 26, 2022 (1) 1 month $ 26,250 $ 26,250 - 0 % (15 ) - - September 28, 2022 12 months $ 52,000 $ 52,000 - 12 % (14 ) - $ 8,420 September 28, 2022 9 months $ 262,500 $ 262,500 $ 12,500 12 % (18 ) - $ 50,005 $ 17,142,974 $ 1,794,220 $ 984,083 $ 8,496,019 Less remaining debt discount $ 434,313 Total convertible debt $ 16,708,661 Notes: (1) The Note is past due. The Company and the lender are negotiating in good faith to extend the loan. (2) The Company and lenders have entered into Standstill and Forbearance Agreements (as described below). (3) Note is secured by the assets of the Company’s subsidiary, PBI Agrochem, Inc. and interest rate is 40.9 (4) During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate. (5) The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date. (6) Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion (7) Notes are convertible before maturity at $ 2.50 (8) Notes can be converted at the lesser of $ 2.5 25 35 (9) Conversion price of this note is $ 2.50 25 25 (10) Notes are convertible upon an Event of Default at 75% multiplied by the lowest trading price for the common stock during the five days prior to the conversion. (11) Loans can be voluntarily converted before maturity at $ 2.50 2.50 10 (12) Notes are convertible at $ 2.50 75 (13) During the nine months ended September 30, 2022, the Company extended 10 loans totaling $ 1,700,000 2,909,561 759,900 (14) These notes can be voluntary converted at lower of 1) $ 2.50 2.50 (15) These notes can be voluntary converted at lower of 1) $ 2.50 2.50 (16) Conversion price is lower of (i) $ 2.50 (17) Conversion price is $ 2.50 (18) Note can be converted at a Voluntary Conversion Price which is the lower of 1) $ 2.50 2.50
Schedule of Non Convertible Debt	The following is a detail of the non-convertible debt: Schedule of Non Convertible Debt Principal Balance Note Original Term Inception September December Interest Rate Security Accredited investor 1 9 3/21/17 $ 170,000 $ 170,000 10 % Unsecured Accredited investor 2 13 9/19/19 & 2/28/20 691,500 691,500 7.5 % Unsecured (1) On Deck Capital 12 4/29/22 29,807 - 2.5 % (2) Unsecured Totals $ 891,307 $ 861,500 (1) As of September 30, 2022 the Company owes $ 691,500 100,000 3 3.50 (2) Rate is per month.
Schedule of Merchant Agreements	The following table shows our Merchant Agreements as of September 30, 2022: Schedule of Merchant Agreements Issue Date Purchase Price Purchase Amount Outstanding Balance Payment Frequency Payment Rate Deferred Finance Fees 12/21/21 $ 400,000 $ 520,000 $ 65,126 Weekly $ 11,305 $ 6,000 5/11/22 $ 225,000 $ 308,250 $ 79,562 Weekly $ 11,009 - 6/28/22 $ 250,000 $ 337,250 $ 125,575 Daily $ 2,595 - 7/21/22 $ 180,000 $ 242,820 $ 114,081 Daily $ 1,868 - 8/8/22 $ 140,000 $ 190,260 $ 96,645 Daily $ 1,586 - 9/21/22 $ 190,000 $ 256,310 $ 183,479 Daily $ 1,972 - $ 1,385,000 $ 1,854,890 $ 664,468 The following table shows our Merchant Agreements as of December 31, 2021: Inception Date Purchase Price Purchased Amount Outstanding Balance Payment frequency Payment Rate Deferred Fees December 21, 2021 $ 400,000 $ 520,000 $ 390,120 Weekly $ 11,305 $ 6,000 July 6, 2021 125,000 166,250 8,790 Daily $ 1,279 2,500 $ 525,000 $ 686,250 $ 398,910 $ 8,500
Schedule of Related Party Debt	Schedule of Related Party Debt Principal Balance Note September 30, 2022 December 31, 2021 Interest rate Security Candy Schumacher $ 70,400 $ - 12 % Unsecured Jeff Peterson 222,200 - 10 % (1) Unsecured Richard Schumacher 165,550 - 12 % Unsecured Accredited investor 3 110,000 - 12 % Unsecured Accredited investor 4 16,500 $ - 12 % Unsecured Totals $ 584,650 $ - Unamortized debt discount 19,149 - Total current notes due $ 565,501 $ -

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Preferred Stock Outstanding	Schedule of Preferred Stock Outstanding September 30, 2022 December 31, 2021 Series D Convertible Preferred Stock, $ .01 par value; 850 shares authorized; 300 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively (Liquidation value of $ 300,000 ) 3 3 Series G Convertible Preferred Stock, $ .01 par value; 240,000 shares authorized; 80,570 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 806 806 Series H Convertible Preferred Stock, $ .01 par value; 10,000 shares authorized; 10,000 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 100 100 Series J Convertible Preferred Stock, $ .01 par value; 6,250 shares authorized; 3,458 and 3,458 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 35 35 Series K Convertible Preferred Stock, $ .01 par value; 15,000 shares authorized; 6,880 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 68 68 Series AA Convertible Preferred Stock, $ .01 par value; 10,000 shares authorized; 8,645 and 8,649 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively 86 87 Series H2 Convertible Preferred Stock, $ .01 par value; 21 shares authorized; 21 shares issued and outstanding on September 30, 2022 and December 31, 2021, respectively - - Series A Junior Participating Preferred Stock, $ .01 20,000 no - - Series A Convertible Preferred Stock, $ .01 313,960 no - - Series B Convertible Preferred Stock, $ .01 279,256 no - - Series C Convertible Preferred Stock, $ .01 88,098 no - - Series E Convertible Preferred Stock, $ .01 500 no - - Total Convertible Preferred Shares $ 1,098 $ 1,099
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following table summarizes information concerning options and warrants outstanding and exercisable: Schedule of Concerning Options and Warrants Outstanding and Exercisable Stock Options Warrants Weighted Weighted Shares price Shares price Shares Total Balance outstanding, December 31, 2021 1,333,101 $ 0.72 16,207,108 $ 3.50 17,540,209 17,308,567 Granted - - 277,500 3.50 277,500 Exercised (25,279 ) 0.69 - - (25,279 ) Expired/forfeited - - (190,840 ) $ 3.50 (190,840 ) Balance outstanding, September 30, 2022 1,307,822 $ 0.72 16,293,768 $ 3.50 17,601,590 17,533,679
Schedule of Loans Obligated to Issue Shares	As profiled in the following table, for five loans we are obligated to issue common stock if not paid by defined dates. Schedule of Loans Obligated to Issue Shares Loan Loan Issuance Date Loan Principal % of Loan Principal Issuable Defined Date Shares Issuable Frequency Loan 1 July 21, 2020 $ 115,000 0.0435 % September 30, 2020 Monthly Loan 2 September 21, 2020 $ 345,000 0.0362 % November 16, 2020 Weekly Loan 3 October 22, 2020 $ 115,000 0.0652 % December 1, 2020 Weekly Loan 4 October 21, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly Loan 5 November 1, 2021 $ 189,750 0.0435 % January 2, 2022 Monthly

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Product Information [Line Items]
Revenue	$ 144,032	$ 518,365	$ 1,122,169	$ 1,687,166
Transferred at Point in Time [Member]
Product Information [Line Items]
Revenue	103,000	392,000	903,000	1,361,000
Transferred over Time [Member]
Product Information [Line Items]
Revenue	41,000	126,000	219,000	326,000
Hardware [Member]
Product Information [Line Items]
Revenue	1,000	276,000	532,000	989,000
Consumables [Member]
Product Information [Line Items]
Revenue	49,000	45,000	165,000	191,000
Contract Research Services [Member]
Product Information [Line Items]
Revenue		100,000	125,000	242,000
Sample Preparation Accessories [Member]
Product Information [Line Items]
Revenue	41,000	39,000	93,000	108,000
Technical Support Extended Service Contracts [Member]
Product Information [Line Items]
Revenue	41,000	26,000	94,000	84,000
Agrochem Products [Member]
Product Information [Line Items]
Revenue	10,000	17,000	93,000	17,000
Shipping and Handling [Member]
Product Information [Line Items]
Revenue	2,000	11,000	20,000	46,000
Others [Member]
Product Information [Line Items]
Revenue		4,000		10,000
North America [Member]
Product Information [Line Items]
Revenue	138,000	351,000	709,000	1,036,000
Europe [Member]
Product Information [Line Items]
Revenue	13,000	57,000	61,000	244,000
Asia [Member]
Product Information [Line Items]
Revenue	$ (7,000)	$ 110,000	$ 352,000	$ 407,000

Schedule of Contract Balances (

Schedule of Contract Balances (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Receivables, which are included in ‘Accounts Receivable’	$ 166	$ 155
Contract liabilities (deferred revenue)	$ 127	$ 41

Schedule of Future Related to P

Schedule of Future Related to Performance Obligations (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 127
2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	32
2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Extended warranty service	$ 95

Schedule of Customer Concentrat

Schedule of Customer Concentration Risk Percentage (Details) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Top Five Customers [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	42%	56%	31%	42%
Top Five Customers [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage			84%		82%
Federal Agencies [Member] | Revenue Benchmark [Member]
Product Information [Line Items]
Concentration credit risk percentage	4%	3%	1%	6%
Federal Agencies [Member] | Accounts Receivable [Member]
Product Information [Line Items]
Concentration credit risk percentage			0%		5%

Schedule of Computation of Loss

Schedule of Computation of Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Net loss attributable to common stockholders	$ (4,893,946)	$ (6,199,176)	$ (12,913,826)	$ (18,387,204)
Weighted average common stock shares outstanding	11,131,742	7,561,728	10,429,817	6,083,017
Loss per common share – basic and diluted	$ (0.44)	$ (0.82)	$ (1.24)	$ (3.02)

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	33,217,416	32,087,170
Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	1,307,822	1,342,490
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	6,471,034	5,330,318
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	16,293,768	16,265,570
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	26,857	26,857
Series H Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	33,334	33,334
Series H Two Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	115,267	115,267
Series K Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	229,334	229,334
Series AA Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,645,000	8,649,000

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total stock-based compensation expense	$ 32,427	$ 95,248	$ 128,984	$ 219,943
Cost of Sales [Member]
Total stock-based compensation expense	2,184	8,664	8,694	18,824
Research and Development Expense [Member]
Total stock-based compensation expense	9,499	43,031	37,803	95,384
Selling and Marketing Expense [Member]
Total stock-based compensation expense	4,583	7,168	18,166	17,650
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 16,161	$ 36,385	$ 64,321	$ 88,085

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Financing Receivable, Past Due [Line Items]
Total Financial Assets	$ 51,929	$ 59,976
Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	51,929	59,976
Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	51,929	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets	51,929	59,976
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Financing Receivable, Past Due [Line Items]
Total Financial Assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jan. 01, 2022	Dec. 31, 2021
Cumulative effect of adoption, adjustment in additional paid in capital	$ 67,041,489		$ 67,041,489			$ 64,261,048
Cumulative effect of adoption, adjustment in accumulated deficit	$ (128,936,078)		$ (128,936,078)			$ (118,277,468)
Forfeiture rate	5%		5%
Share based compensation	$ 32,427	$ 95,248	$ 128,984	$ 219,943
Nexity Global SA [Member]
Sale of stock, number of shares issued in transaction			100,250
Investment owned fair value	$ 51,929		$ 51,929
Marketable securities realized gain loss			$ 8,047
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative effect of adoption, adjustment in additional paid in capital					$ 2,728,243
Cumulative effect of adoption, adjustment in accumulated deficit					$ 2,255,216

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 57,971
2023	149,299
2024	64,393
2025	66,969
2026	51,778
Thereafter
Total	$ 390,410

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended		12 Months Ended
	Aug. 09, 2021	Apr. 30, 2012	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Battelle Memorial Institute [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fees						$ 5,000	$ 4,000	$ 3,000	$ 2,000	$ 1,200
Target Discovery Inc [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Mimimum royalty fees			$ 60,000		$ 60,000
Payments for fees		$ 1,400	$ 65,100	$ 44,600
Professional and contract services expense		$ 2,000
Medford lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease expire date			Dec. 30, 2023
Annual cost of living payment			$ 7,282
Lessee operating lease description			The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term
Operating lease liability			$ 221,432
Estimated borrowing rate			12%
Sparks lease [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lessee operating lease description	On August 9, 2021, we entered into an operating lease agreement for our warehouse space in Sparks, NV (the “Sparks Lease”) for the period from September 1, 2021 through September 30, 2026. The lease contains escalating payments during the lease period. The lease can be extended for an additional three years if the Company provides notice at least six months prior to the expiration of the current lease term
Operating lease liability			$ 239,327
Estimated borrowing rate			12%
Corporate Office [Member]
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Lease monthly payments			$ 6,950
Lease expire date			Dec. 31, 2022

Schedule of Convertible Debts a

Schedule of Convertible Debts and Outstanding Balances (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares
Line of Credit Facility [Line Items]
Disscount conversion percentage	35%
Fixed Rate Convertible Notes [Member]
Line of Credit Facility [Line Items]
Convertible Debt	$ 16,708,661
Debt Conversion, Original Debt, Amount	1,794,220
Debt Instrument, Fee Amount	984,083
Debt Instrument, Convertible, Beneficial Conversion Feature	8,496,019
Long-Term Debt, Gross	17,142,974
Debt Instrument, Unamortized Discount	434,313
Convertible Notes One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	380,000
Convertible Debt	98,544
Debt Conversion, Original Debt, Amount	$ 15,200
Debt conversion interest rate percentage	8%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 15,200
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 332,407
Debt Conversion, Original Debt, Issuance Date of Debt	May 17, 2018	[1],[2]
Term	12 months	[1],[2]
Convertible Notes Two [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Debt Conversion, Original Debt, Amount	$ 2,500
Debt conversion interest rate percentage	24%
Debt conversion price | $ / shares	$ 7.50
Debt Instrument, Fee Amount	$ 2,500
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 03, 2019	[2],[3]
Term	6 months	[2],[3]
Convertible Notes Three [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	302,484
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	8%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 40,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 70,631
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 04, 2019	[1],[2]
Term	9 months	[1],[2]
Convertible Notes Four [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	4%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 5,750
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 15,460
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 19, 2019	[1],[2]
Term	12 months	[1],[2]
Convertible Notes Five [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 78,750
Convertible Debt	78,750
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	4%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 3,750
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 13,759
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 27, 2019	[1],[2]
Term	12 months	[1],[2]
Convertible Notes Six [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 78,750
Convertible Debt	78,750
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	4%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 3,750
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Oct. 24, 2019	[1],[2]
Term	12 months	[1],[2]
Convertible Notes Seven [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 385,000
Convertible Debt	320,000
Debt Conversion, Original Debt, Amount	$ 35,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 35,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 90,917
Debt Conversion, Original Debt, Issuance Date of Debt	Nov. 15, 2019	[2]
Term	12 months	[2]
Convertible Notes Eight [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 330,000
Convertible Debt	330,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 91,606
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 02, 2020	[2]
Term	12 months	[2]
Convertible Notes Nine [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 247,500
Convertible Debt	247,500
Debt Conversion, Original Debt, Amount	$ 22,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 22,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 89,707
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 24, 2020	[2]
Term	12 months	[2]
Convertible Notes Ten [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 363,000
Convertible Debt	363,000
Debt Conversion, Original Debt, Amount	$ 33,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 33,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 297,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 29, 2020	[2]
Term	12 months	[2]
Convertible Notes Eleven [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 275,000
Convertible Debt	275,000
Debt Conversion, Original Debt, Amount	$ 25,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 25,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 225,000
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 12, 2020	[2]
Term	12 months	[2]
Convertible Notes Twelve [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 165,000
Convertible Debt	165,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 15,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 135,000
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 19, 2020	[2]
Term	12 months	[2]
Convertible Notes Thirteen [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 330,000
Convertible Debt	330,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 232,810
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 11, 2020	[2]
Term	12 months	[2]
Convertible Notes Fourteen [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 165,000
Convertible Debt	165,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 15,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 60,705
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 13, 2020	[2]
Term	12 months	[2]
Convertible Notes Fifteen [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 111,100
Convertible Debt	111,100
Debt Conversion, Original Debt, Amount	$ 10,100
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,100
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 90,900
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 26, 2020	[2]
Term	12 months	[2]
Convertible Notes Sixteen [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 276,100
Convertible Debt	276,100
Debt Conversion, Original Debt, Amount	$ 25,100
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 25,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 221,654
Debt Conversion, Original Debt, Issuance Date of Debt	Apr. 08, 2020	[2]
Term	12 months	[2]
Convertible Notes Seventeen [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 143,750
Convertible Debt	143,750
Debt Conversion, Original Debt, Amount	$ 18,750
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 96,208
Debt Conversion, Original Debt, Issuance Date of Debt	Apr. 17, 2020	[2]
Term	12 months	[2]
Convertible Notes Eighteen [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 546,250
Convertible Debt	546,250
Debt Conversion, Original Debt, Amount	$ 71,250
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 47,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 427,500
Debt Conversion, Original Debt, Issuance Date of Debt	Apr. 30, 2020	[2]
Term	12 months	[2]
Convertible Notes Nineteen [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 460,000
Convertible Debt	460,000
Debt Conversion, Original Debt, Amount	$ 60,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 40,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 360,000
Debt Conversion, Original Debt, Issuance Date of Debt	May 06, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 546,250
Convertible Debt	221,250
Debt Conversion, Original Debt, Amount	$ 46,250
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 35,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 439,500
Debt Conversion, Original Debt, Issuance Date of Debt	May 18, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 902,750
Convertible Debt	652,750
Debt Conversion, Original Debt, Amount	$ 92,750
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 58,900
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 708,500
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 02, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty Two [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 57,500
Convertible Debt	57,500
Debt Conversion, Original Debt, Amount	$ 7,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 5,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 45,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 12, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty Three [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 138,000
Convertible Debt	138,000
Debt Conversion, Original Debt, Amount	$ 18,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 12,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 108,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 22, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty Four [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 586,500
Convertible Debt	586,500
Debt Conversion, Original Debt, Amount	$ 76,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 51,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 400,234
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 07, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty Five [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 362,250
Convertible Debt	362,250
Debt Conversion, Original Debt, Amount	$ 47,250
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 31,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 185,698
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 17, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty Six [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 345,000
Convertible Debt	345,000
Debt Conversion, Original Debt, Amount	$ 45,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 241,245
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 29, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty Seven [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 24,875
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 21, 2020	[2],[4]
Term	12 months	[2]
Convertible Notes Twenty Eight [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 762,450
Convertible Debt	462,450
Debt Conversion, Original Debt, Amount	$ 69,450
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 66,300
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 580,124
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 14, 2020	[2]
Term	12 months	[2]
Convertible Notes Twenty Nine [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 391,000
Convertible Debt	391,000
Debt Conversion, Original Debt, Amount	$ 51,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 34,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 231,043
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 10, 2020	[2]
Term	12 months	[2]
Convertible Notes Thirty [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 345,000
Convertible Debt	345,000
Debt Conversion, Original Debt, Amount	$ 45,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 66,375
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 21, 2020	[2],[4]
Term	12 months	[2]
Convertible Notes Thirty One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	15,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 20,500
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 23, 2020	[2]
Term	12 months	[2]
Convertible Notes Thirty Two [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 299,000
Convertible Debt	299,000
Debt Conversion, Original Debt, Amount	$ 39,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 26,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 197,882
Debt Conversion, Original Debt, Issuance Date of Debt	Dec. 03, 2020	[2]
Term	12 months	[2]
Convertible Notes Thirty Three [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 18,875
Debt Conversion, Original Debt, Issuance Date of Debt	Oct. 22, 2020	[2],[4]
Term	12 months	[2]
Convertible Notes Thirty Four [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 230,000
Convertible Debt	230,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 20,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 180,000
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 17, 2021	[2]
Term	12 months	[2]
Convertible Notes Thirty Five [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 55,000
Convertible Debt	55,000
Debt Conversion, Original Debt, Amount	$ 5,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 36,431
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 23, 2021	[2]
Term	12 months	[2]
Convertible Notes Thirty Six [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 402,500
Convertible Debt	402,500
Debt Conversion, Original Debt, Amount	$ 52,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 35,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 312,551
Debt Conversion, Original Debt, Issuance Date of Debt	May 06, 2021	[2]
Term	12 months	[2]
Convertible Notes Thirty Seven [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 230,000
Convertible Debt	230,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 20,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 144,760
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 17, 2021	[2]
Term	12 months	[2]
Convertible Notes Thirty Eight [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 977,500
Convertible Debt	977,500
Debt Conversion, Original Debt, Amount	$ 127,500
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 773,802
Debt Conversion, Original Debt, Issuance Date of Debt	Jun. 25, 2021	[2]
Term	12 months	[2]
Convertible Notes Thirty Nine [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Debt Conversion, Original Debt, Amount	$ 1,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (14)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 7,948
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 04, 2022	[5]
Term	12 months	[2]
Convertible Notes Fourty [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 700,000
Convertible Debt	700,000
Debt Conversion, Original Debt, Amount	$ 84,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (6)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 31, 2022	[5]
Term	6 months	[2]
Convertible Notes Fourty One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 115,000
Convertible Debt	115,000
Debt Conversion, Original Debt, Amount	$ 15,000
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 10,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 90,000
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 03, 2021	[2]
Term	12 months	[2]
Convertible Notes Fourty Two [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 260,000
Convertible Debt	185,000
Debt Conversion, Original Debt, Amount	$ 10,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (15)
Debt Instrument, Fee Amount	$ 2,000
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 01, 2022	[5]
Term	6 months	[2]
Convertible Notes Fourty Three [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	500,000
Debt Conversion, Original Debt, Amount	$ 30,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (11)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 04, 2022	[2],[5]
Term	8 months	[2]
Convertible Notes Fourty Four [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 500,000
Convertible Debt	500,000
Debt Conversion, Original Debt, Amount	$ 25,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (11)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	May 13, 2022	[5],[6]
Term	7 months	[2]
Convertible Notes Fourty Five [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 52,000
Convertible Debt	52,000
Debt Conversion, Original Debt, Amount	$ 2,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 2,000
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Jan. 19, 2022	[2],[5]
Term	6 months	[2]
Convertible Notes Fourty Six [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 352,188
Convertible Debt	352,188
Debt Conversion, Original Debt, Amount	$ 45,938
Debt conversion interest rate percentage	15%
Debt conversion price | $ / shares	$ (8)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 16, 2022	[5],[7]
Term	1 month	[2]
Convertible Notes Fourty Seven [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 140,875
Convertible Debt	140,875
Debt Conversion, Original Debt, Amount	$ 18,375
Debt conversion interest rate percentage	15%
Debt conversion price | $ / shares	$ (8)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 26, 2022	[2],[5],[7]
Term	1 month	[2]
Convertible Notes Fourty Eight [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Debt Conversion, Original Debt, Amount	$ 24,750
Debt conversion interest rate percentage	10%
Debt conversion price | $ / shares	$ (9)
Debt Instrument, Fee Amount	$ 16,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 148,500
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 31, 2021	[2]
Term	12 months	[2]
Convertible Notes Fourty Nine [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 65,000
Convertible Debt	65,000
Debt Conversion, Original Debt, Amount	$ 3,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	May 08, 2022	[5]
Term	8 months	[2]
Convertible Notes Fifty [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 100,000
Convertible Debt	100,000
Debt Conversion, Original Debt, Amount	$ 4,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 43,520
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 10, 2021	[2]
Term	8 months	[2]
Convertible Notes Fifty One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Debt Conversion, Original Debt, Amount	$ 12,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 108,801
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 15, 2021	[2]
Term	6 months	[2]
Convertible Notes Fifty Two [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Debt Conversion, Original Debt, Amount	$ 12,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 112,337
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 16, 2021	[2]
Term	6 months	[2]
Convertible Notes Fifty Three [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 125,000
Convertible Debt	125,000
Debt Conversion, Original Debt, Amount	$ 6,250
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 61,876
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 24, 2021	[2]
Term	8 months	[2]
Convertible Notes Fifty Four [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 250,000
Convertible Debt	250,000
Debt Conversion, Original Debt, Amount	$ 37,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (7)
Debt Instrument, Fee Amount	$ 30,000
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 15, 2021	[2]
Term	6 months	[2]
Convertible Notes Fifty Five [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Debt Conversion, Original Debt, Amount	$ 24,750
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 16,500
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 87,332
Debt Conversion, Original Debt, Issuance Date of Debt	Oct. 21, 2021	[2],[4]
Term	12 months	[2]
Convertible Notes Fifty Six [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 189,750
Convertible Debt	189,750
Debt Conversion, Original Debt, Amount	$ 24,750
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 96,991
Debt Conversion, Original Debt, Issuance Date of Debt	Nov. 01, 2021	[2],[4]
Term	12 months	[2]
Convertible Notes Fifty Seven [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 112,000
Convertible Debt	(8,573)
Debt Conversion, Original Debt, Amount	$ 13,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (12)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 29, 2022
Term	8 months	[2]
Convertible Notes Fifty Eight [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 88,987
Convertible Debt	35,737
Debt Conversion, Original Debt, Amount	$ 10,237
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (10)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Feb. 09, 2022
Term	12 months	[2]
Convertible Notes Fifty Nine [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 100,000
Convertible Debt	100,000
Debt Conversion, Original Debt, Amount	$ 5,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 19,614
Debt Conversion, Original Debt, Issuance Date of Debt	Mar. 30, 2022
Term	12 months	[2]
Convertible Notes Sixty [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 95,000
Convertible Debt	95,000
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (12)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 16,234
Debt Conversion, Original Debt, Issuance Date of Debt	Apr. 19, 2022
Term	12 months	[2]
Convertible Notes Sixty Two [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 950,000
Convertible Debt	950,000
Debt Conversion, Original Debt, Amount	$ 57,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount	$ 22,333
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	May 23, 2022
Term	8 months	[2]
Convertible Notes Sixty Three [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 22,000
Convertible Debt	22,000
Debt Conversion, Original Debt, Amount	$ 880
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 6,286
Debt Conversion, Original Debt, Issuance Date of Debt	Jul. 15, 2022
Term	12 months	[2]
Convertible Notes Sixty Four [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 25,000
Convertible Debt	25,000
Debt Conversion, Original Debt, Amount	$ 980
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ 2.50
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 6,412
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 03, 2022
Term	12 months	[2]
Convertible Notes Sixty Five [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 196,319
Convertible Debt	196,319
Debt Conversion, Original Debt, Amount	$ 22,585
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (10)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 10, 2022
Term	12 months	[2]
Convertible Notes Sixty Six [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Debt Conversion, Original Debt, Amount	$ 2,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (16)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 11, 2022
Term	12 months	[2]
Convertible Notes Sixty Seven [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Debt Conversion, Original Debt, Amount	$ 2,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (15)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 7,149
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 17, 2022
Term	12 months	[2]
Convertible Notes Sixty Eight [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 200,000
Convertible Debt	200,000
Debt Conversion, Original Debt, Amount	$ 14,000
Debt conversion interest rate percentage	15%
Debt conversion price | $ / shares	$ (15)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Aug. 24, 2022	[8]
Term	12 months	[2]
Convertible Notes Sixty Nine [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 50,000
Convertible Debt	50,000
Debt Conversion, Original Debt, Amount	$ 2,000
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (14)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 9,845
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 07, 2022
Term	12 months	[2]
Convertible Notes Seventy [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 87,500
Convertible Debt	87,500
Debt Conversion, Original Debt, Amount	$ 11,375
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (12)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 22,430
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 08, 2022
Term	12 months	[2]
Convertible Notes Seventy One [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 113,000
Convertible Debt	113,000
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (17)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 25,651
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 16, 2022	[9]
Term	12 months	[2]
Convertible Notes Seventy Two [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 175,000
Convertible Debt	175,000
Debt Conversion, Original Debt, Amount	$ 22,750
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (12)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 09, 2022
Term	10 months	[2]
Convertible Notes SeventyThree [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 26,250
Convertible Debt	26,250
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	0%
Debt conversion price | $ / shares	$ (15)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 26, 2022	[2]
Term	1 month	[2]
Convertible Notes Seventy Four [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 52,000
Convertible Debt	52,000
Debt Conversion, Original Debt, Amount
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (14)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 8,420
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 28, 2022
Term	12 months	[2]
Convertible Notes Seventy Five [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	$ 262,500
Convertible Debt	262,500
Debt Conversion, Original Debt, Amount	$ 12,500
Debt conversion interest rate percentage	12%
Debt conversion price | $ / shares	$ (18)
Debt Instrument, Fee Amount
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 50,005
Debt Conversion, Original Debt, Issuance Date of Debt	Sep. 28, 2022
Term	9 months	[2]
[1]The Company and lenders have entered into Standstill and Forbearance Agreements (as described below).[2]The Note is past due. The Company and the lender are negotiating in good faith to extend the loan.[3]During the year ended December 31, 2020, the Company entered into a Rate Modification Agreement with this lender. In this agreement the lender agreed to reduce their interest rate and were granted the right to convert loans using a variable conversion price if more than one other variable rate lender converted at a variable rate.[4]The Company has agreed to issue shares of its common stock to lenders if their notes are not repaid by a defined date.[5]During the nine months ended September 30, 2022, the Company extended 10 loans totaling $ 1,700,000 2,909,561 759,900 2.50 2.50 10 40.9 2.50 2.50 2.50

Schedule of Convertible Debts_2

Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Short-Term Debt [Line Items]
Debt instrument lowest trading price	25%
Debt instrument, convertible price per shares	$ 2.50
Debt instrument, convertible, conversion price	$ 2.50
Debt instrument conversion ratio	10
Debt default convertible conversion ratio	75%
Nine Loans [Member]
Short-Term Debt [Line Items]
Proceeds from loans | $	$ 1,700,000
Increase in principal amount | $	$ 2,909,561
Nine Loans [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Shares issued, shares | shares	759,900
Loans [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price	$ 2.50
Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price	$ 2.50
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Debt instrument, description	Loan is not convertible until 180 days from the date of issuance of the Note and following an Event of Default will be convertible at the lowest trading price of the 20 days prior to conversion. The loan is guaranteed by the Company’s Chief Executive Officer, but the lender may only enforce this guarantee after certain conditions have been met, specifically after (i) the occurrence of an Event of Default (as defined in the Note), (ii) the failure of the Company to cure the Default in 10 business days, and (iii) a failure by the Company to issue, or cause to be issued, shares of its common stock upon submission by the lender of a notice of conversion
PBI Agrochem Inc [Member]
Short-Term Debt [Line Items]
Debt instrument lowest trading price	40.90%

Schedule of Non Convertible Deb

Schedule of Non Convertible Debt (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Principle balance		$ 891,307	$ 861,500
Accredited Investor 1 [Member]
Short-Term Debt [Line Items]
Original term		9 months
Inception date		Mar. 21, 2017
Principle balance		$ 170,000	$ 170,000
Debt Instrument, interest rate, stated percentage			10%
Accredited Investor 2 [Member]
Short-Term Debt [Line Items]
Original term		13 months
Principle balance			$ 691,500
Debt Instrument, interest rate, stated percentage			7.50%
Inception date		9/19/19 & 2/28/20
Principle balance		$ 691,500
On Deck Capital [Member]
Short-Term Debt [Line Items]
Original term		12 months
Inception date		Apr. 29, 2022
Principle balance		$ 29,807
Debt Instrument, interest rate, stated percentage	[1]		2.50%
[1]Rate is per month.

Schedule of Non Convertible D_2

Schedule of Non Convertible Debt (Details) (Parenthetical) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Warrants and Rights Outstanding, Term	3 years
Warrant [Member]
Short-Term Debt [Line Items]
Number of warrants issued, shares	277,500	1,558,266
Warrants price	$ 3.50	$ 3.50
Private Investors [Member] | Two Notes [Member]
Short-Term Debt [Line Items]
Debt owes	$ 691,500
Warrants price	$ 3.50
Private Investors [Member] | Two Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Number of warrants issued, shares	100,000

Schedule of Merchant Agreements

Schedule of Merchant Agreements (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 1,385,000	$ 525,000
Purchased Amount	1,854,890	686,250
Outstanding Balance	664,468	398,910
Debt Instrument, Fee Amount		8,500
Merchant Agreements One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	400,000	400,000
Purchased Amount	520,000	520,000
Outstanding Balance	$ 65,126	$ 390,120
Debt Instrument, Frequency of Periodic Payment	Weekly	Weekly
Debt Instrument, Periodic Payment	$ 11,305	$ 11,305
Debt Instrument, Fee Amount	$ 6,000	$ 6,000
Inception date	Dec. 21, 2021	Dec. 21, 2021
Merchant Agreements Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 225,000	$ 125,000
Purchased Amount	308,250	166,250
Outstanding Balance	$ 79,562	$ 8,790
Debt Instrument, Frequency of Periodic Payment	Weekly	Daily
Debt Instrument, Periodic Payment	$ 11,009	$ 1,279
Debt Instrument, Fee Amount		$ 2,500
Inception date	May 11, 2022	Jul. 06, 2021
Merchant Agreements Three [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 250,000
Purchased Amount	337,250
Outstanding Balance	$ 125,575
Debt Instrument, Frequency of Periodic Payment	Daily
Debt Instrument, Periodic Payment	$ 2,595
Debt Instrument, Fee Amount
Inception date	Jun. 28, 2022
Merchant Agreements Four [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 180,000
Purchased Amount	242,820
Outstanding Balance	$ 114,081
Debt Instrument, Frequency of Periodic Payment	Daily
Debt Instrument, Periodic Payment	$ 1,868
Debt Instrument, Fee Amount
Inception date	Jul. 21, 2022
Merchant Agreements Five [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 140,000
Purchased Amount	190,260
Outstanding Balance	$ 96,645
Debt Instrument, Frequency of Periodic Payment	Daily
Debt Instrument, Periodic Payment	$ 1,586
Debt Instrument, Fee Amount
Inception date	Aug. 08, 2022
Merchant Agreements Six [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase Price	$ 190,000
Purchased Amount	256,310
Outstanding Balance	$ 183,479
Debt Instrument, Frequency of Periodic Payment	Daily
Debt Instrument, Periodic Payment	$ 1,972
Debt Instrument, Fee Amount
Inception date	Sep. 21, 2022

Schedule of Related Party Debt

Schedule of Related Party Debt (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Principle balance		$ 891,307	$ 861,500
Candy Schumacher [Member]
Defined Benefit Plan Disclosure [Line Items]
Principle balance		70,400
Debt Instrument, interest rate, stated percentage			12%
Jeff Peterson [Member]
Defined Benefit Plan Disclosure [Line Items]
Principle balance		222,200
Debt Instrument, interest rate, stated percentage	[1]		10%
Richard Schumacher [Member]
Defined Benefit Plan Disclosure [Line Items]
Principle balance		165,550
Debt Instrument, interest rate, stated percentage			12%
Accredited Investor 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Principle balance		110,000
Debt Instrument, interest rate, stated percentage			12%
Accredited Investor 4 [Member]
Defined Benefit Plan Disclosure [Line Items]
Principle balance		16,500
Debt Instrument, interest rate, stated percentage			12%
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Principle balance		584,650
Principle balance		19,149
Principle balance		$ 565,501
[1]Rate is per month.

Convertible Debt and Other De_3

Convertible Debt and Other Debt (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Net proceeds from convertible debt		$ 3,428,249	$ 5,054,500
Fixed rate, per share	$ 2.50	$ 2.50
Losses on extinguishment of debt		$ (1,809,249)	(23,004)
Repayment of related party debt		259,600	$ 256,600
Standstill and Forbearance Agreements [Member]
Short-Term Debt [Line Items]
Convertible note outstanding	$ 673,528	673,528
Company incurred interest, penalties, and fees	$ 202,058	$ 606,158
Economic Injury Disaster Loan Program [Member]
Short-Term Debt [Line Items]
Debt term		30 years
Debt instrument interest rate	3.75%	3.75%
Debt instrument, face amount	$ 150,000	$ 150,000
Monthly payments for principal and interest		731
One Lender [Member]
Short-Term Debt [Line Items]
Convertible note outstanding	9,400,000	9,400,000
Lender [Member]
Short-Term Debt [Line Items]
Convertible note outstanding	$ 17,100,000	$ 17,100,000
Minimum [Member] | Merchant Agreements [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate	2.80%	2.80%
Maximum [Member] | Merchant Agreements [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate	9.10%	9.10%
Convertible Debt [Member]
Short-Term Debt [Line Items]
Net proceeds from convertible debt		$ 3,921,617
Amortization of Debt Discount (Premium)		$ 1,728,846
Convertible Debt [Member] | Convertible Common Stock [Member]
Short-Term Debt [Line Items]
Fixed rate, per share	$ 2.50	$ 2.50
Convertible notes debt fair value	$ 606,169	$ 606,169
Convertible Debt [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt term		1 month
Debt instrument interest rate	12%	12%
Convertible Debt [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt term		12 months
Debt instrument interest rate	15%	15%
Convertible Debentures and Other Convertible Notes [Member]
Short-Term Debt [Line Items]
Debt Instrument, Unamortized Discount	$ 434,313	$ 434,313
New Loan [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate	10%	10%
Losses on extinguishment of debt		$ 1,809,249
Short-term Non-Convertible Loan [Member]
Short-Term Debt [Line Items]
Fixed rate, per share	$ 2.50	$ 2.50
Original issue discount percentage	10%	10%
Related party debt		$ 844,250
Repayment of related party debt		$ 259,600
Short-term Non-Convertible Loan [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate	12%	12%
Short-term Non-Convertible Loan [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument interest rate	120%	120%

Schedule of Preferred Stock Out

Schedule of Preferred Stock Outstanding (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 1,098	$ 1,099
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding	1,098	1,099
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 3	$ 3
Preferred stock, shares outstanding	300	300
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 806	$ 806
Preferred stock, shares outstanding	80,570	80,570
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 100	$ 100
Preferred stock, shares outstanding		10,000
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 35	$ 35
Preferred stock, shares outstanding	3,458	3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 68	$ 68
Preferred stock, shares outstanding	6,880	6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares	$ 86	$ 87
Preferred stock, shares outstanding	8,645	8,649
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	21	21
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Series A Junior Participating Preferred Stock, $.01 par value, 20,000 shares authorized, no shares outstanding
Preferred stock, shares outstanding	0	0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total Convertible Preferred Shares
Preferred stock, shares outstanding	0	0

Schedule Of Preferred Stock O_2

Schedule Of Preferred Stock Outstanding (Details) (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	850	850
Preferred stock, shares issued	300	300
Preferred stock, shares outstanding	300	300
Preferred Stock, Liquidation Preference, Value	$ 300,000	$ 300,000
Series H Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares outstanding		10,000
Series G Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	80,570	80,570
Preferred stock, shares outstanding	80,570	80,570
Series J Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	6,250	6,250
Preferred stock, shares issued	3,458	3,458
Preferred stock, shares outstanding	3,458	3,458
Series K Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000	15,000
Preferred stock, shares issued	6,880	6,880
Preferred stock, shares outstanding	6,880	6,880
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	8,645	8,649
Preferred stock, shares outstanding	8,645	8,649
Series H2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	21	21
Preferred stock, shares issued	21	21
Preferred stock, shares outstanding	21	21
Series A Junior Participating Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares outstanding	0	0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	313,960	313,960
Preferred stock, shares outstanding	0	0
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	279,256	279,256
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	88,098	88,098
Preferred stock, shares outstanding	0	0
Series E Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	500	500
Preferred stock, shares outstanding	0	0

Schedule of Concerning Options

Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	17,540,209
Total exercisable, beginning balance	17,308,567
Shares, granted	277,500
Shares, exercised	(25,279)
Shares, expired/forfeited	(190,840)
Shares, ending balance	17,601,590
Total exercisable, ending balance	17,533,679
Stock Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	1,333,101
Weighted average price per share, beginning balance | $ / shares	$ 0.72
Shares, granted
Weighted average price per share, granted | $ / shares
Shares, exercised	(25,279)
Weighted average price per share, exercised | $ / shares	$ 0.69
Shares, expired/forfeited
Weighted average price per share, expired/forfeited | $ / shares
Shares, ending balance	1,307,822
Weighted average price per share, ending balance | $ / shares	$ 0.72
Total exercisable, ending balance	1,239,911
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, beginning balance	16,207,108
Weighted average price per share, beginning balance | $ / shares	$ 3.50
Shares, granted	277,500
Weighted average price per share, granted | $ / shares	$ 3.50
Shares, exercised
Weighted average price per share, exercised | $ / shares
Shares, expired/forfeited	(190,840)
Weighted average price per share, expired/forfeited | $ / shares	$ 3.50
Shares, ending balance	16,293,768
Weighted average price per share, ending balance | $ / shares	$ 3.50

Schedule of Loans Obligated to

Schedule of Loans Obligated to Issue Shares (Details)	9 Months Ended
	Sep. 30, 2022 USD ($)
Loans 1 [Member]
Short-Term Debt [Line Items]
Loan issuance date	Jul. 21, 2020
Loan principal	$ 115,000
Percentage of loan principal issuable	0.0435%
Defined date	Sep. 30, 2020
Debt Instrument, Description	Monthly
Loans 2 [Member]
Short-Term Debt [Line Items]
Loan issuance date	Sep. 21, 2020
Loan principal	$ 345,000
Percentage of loan principal issuable	0.0362%
Defined date	Nov. 16, 2020
Debt Instrument, Description	Weekly
Loans 3 [Member]
Short-Term Debt [Line Items]
Loan issuance date	Oct. 22, 2020
Loan principal	$ 115,000
Percentage of loan principal issuable	0.0652%
Defined date	Dec. 01, 2020
Debt Instrument, Description	Weekly
Loans 4 [Member]
Short-Term Debt [Line Items]
Loan issuance date	Oct. 21, 2021
Loan principal	$ 189,750
Percentage of loan principal issuable	0.0435%
Defined date	Jan. 02, 2022
Debt Instrument, Description	Monthly
Loans 5 [Member]
Short-Term Debt [Line Items]
Loan issuance date	Nov. 01, 2021
Loan principal	$ 189,750
Percentage of loan principal issuable	0.0435%
Defined date	Jan. 02, 2022
Debt Instrument, Description	Monthly

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 30, 2021
Class of Stock [Line Items]
Options outstanding, shares	17,601,590						17,601,590		17,540,209
Number of options, exercisable	17,533,679						17,533,679		17,308,567
Interest expense	$ 2,034,021			$ 3,330,101			$ 6,448,771	$ 11,524,306
Shares isused for options exercised, shares							25,279
Shares isused for options exercised, value		$ 17,443				$ 14,773
Number of common stock for services rendered	167,375	67,800	$ 77,700	341,000		238,512
Fair value of dividends paid in kind	$ 1,050,475	$ 191,303	472,900
Convertible debt issuances value			$ 350,500	$ 2,240,740	$ 231,250	$ 118,000
Fair value of warrant								$ 245,635
Exercise price, per share	$ 2.50						$ 2.50
Acquisition of warrant, shares								200,100
Loss on settlement of liabilities							$ 1,809,249	$ 23,004
Common stock, par value	$ 0.01						$ 0.01		$ 0.01
Common stock, par value								$ 1,015,000
Securities Purchase Agreements [Member]
Class of Stock [Line Items]
Purchase from warrants				$ 3.50				$ 3.50
Common stock, par value								$ 1,015,000
Purchase from warrants								406,000
Lender [Member]
Class of Stock [Line Items]
Shares issued, price per share				$ 0.69				$ 0.69
Payment in Kind (PIK) Note [Member]
Class of Stock [Line Items]
Common stock issued for debt extension, shares							1,172,100	2,431,182
Fair value of dividends paid in kind							$ 2,196,278	$ 5,600,000
Dividends Paid In Kind [Member]
Class of Stock [Line Items]
Common stock issued for debt extension, shares							170,306	56,067
Fair value of dividends paid in kind							$ 306,333	$ 114,298
Debt Settlement [Member]
Class of Stock [Line Items]
Shares isused for options exercised, shares							25,279	21,411
Shares isused for options exercised, value							$ 17,443
Issued For Services Rendered [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares							190,500	248,200
Number of common stock for services rendered							$ 312,875	$ 579,512
Debt Extension [Member]
Class of Stock [Line Items]
Common stock issued for debt extension, shares							1,028,800	1,035,996
Fair value of dividends paid in kind							$ 1,714,678	$ 2,589,990
Conversion of Debt Extension [Member]
Class of Stock [Line Items]
Issuance of stock, shares							140,200	347,650
Convertible debt issuances value							$ 350,500	$ 551,198
New Conversion Debt [Member]
Class of Stock [Line Items]
Common stock issued for debt extension, shares							368,500
Fair value of dividends paid in kind							$ 512,593
Professional Services [Member]
Class of Stock [Line Items]
Number of common stock for services rendered, shares							57,500
Accredited Investor and Consultants [Member]
Class of Stock [Line Items]
Shares of restricted stock to accredited investors							3,100,085	4,176,796
Stock Options [Member]
Class of Stock [Line Items]
Options outstanding, shares	1,307,822						1,307,822		1,333,101
Weighted average exercise price	$ 0.72						$ 0.72		$ 0.72
Weighted average remaining term							6 years 11 months 15 days
Number of options, exercisable	1,239,911						1,239,911
Shares isused for options exercised, shares							25,279
Common Stock [Member]
Class of Stock [Line Items]
Common stock issued for debt extension, shares	707,900	106,400	214,500					200
Interest expense	$ 634,305						$ 2,196,278
Shares isused for options exercised, shares		25,279				21,411
Shares isused for options exercised, value		$ 253				$ 214
Number of common stock for services rendered, shares	113,500	40,000	37,000	135,800		112,400
Number of common stock for services rendered	$ 1,135	$ 400	$ 370	$ 1,358		$ 1,124
Fair value of dividends paid in kind	$ 7,079	1,064	$ 2,145
Issuance of stock, shares			140,200	896,296	92,500	47,200
Convertible debt issuances value			$ 1,402	$ 8,963	$ 925	$ 472
Common Stock [Member] | Securities Purchase Agreements [Member]
Class of Stock [Line Items]
Common stock issued for debt extension, shares								406
Issuance of stock, shares								1,000
Common stock, par value				$ 0.01				$ 0.01
Common Stock [Member] | Five Loans [Member]
Class of Stock [Line Items]
Common stock issued for debt extension, shares	389,500						1,172,100
Warrant [Member]
Class of Stock [Line Items]
Options outstanding, shares	16,293,768						16,293,768		16,207,108
Weighted average exercise price	$ 3.50						$ 3.50		$ 3.50
Common stock issued for debt extension, shares							277,500	1,558,266
Shares isused for options exercised, shares
Shares isused for options exercised, value
Number of common stock for services rendered
Fair value of dividends paid in kind
Convertible debt issuances value
Fair value of warrant							$ 280,608	$ 2,000,000
Purchase from warrants	$ 3.50			$ 3.50			$ 3.50	$ 3.50
Debt term								5 years
Warrant [Member] | Minimum [Member]
Class of Stock [Line Items]
Debt term							3 years	3 years
Exercise price, per share				3.50				$ 3.50
Warrant [Member] | Maximum [Member]
Class of Stock [Line Items]
Debt term							5 years	5 years
Exercise price, per share				$ 5				$ 5
Warrant [Member] | New Conversion Debt [Member]
Class of Stock [Line Items]
Warrant issued	120,000			36,290			120,000	36,290
Warrant issued for debt extension							100,000
Unvested Stock-Based Awards [Member]
Class of Stock [Line Items]
Unvested stock based awards	$ 43,971						$ 43,971
Unrecognized compensation, period							8 months 12 days
Closing stock price	$ 1.30						$ 1.30
Options outstanding and exercisable intrinsic value	$ 751,466						$ 751,466
2021 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Common stock, capital shares reserved for future issuance										3,000,000
Options outstanding, shares	1,307,822						1,307,822
Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	1,000,000						1,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01						$ 0.01
Preferred Stock, Shares Issued	1,000,000						1,000,000
Series AA Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	10,000						10,000		10,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01						$ 0.01		$ 0.01
Preferred Stock, Shares Issued	8,645						8,645		8,649
Conversion of stock, shares converted							4,400

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		2 Months Ended	9 Months Ended
	Oct. 05, 2022	Nov. 18, 2022	Sep. 30, 2022	Sep. 30, 2021	Oct. 24, 2022	Oct. 18, 2022
Subsequent Event [Line Items]
Proceeds from related party debt			$ 762,500	$ 194,600
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from related party debt		$ 10
Debt instrument description		due upon demand, 10% OID and 10% interest per month, convertible into Company’s common shares at $2.50 per share
Debt interest rate		10%
Subsequent Event [Member] | New Merchant Cash Loan [Agreement]
Subsequent Event [Line Items]
Proceeds from related party debt		$ 580,000
Debt instrument description		loan term are from 2 to 12 months; interest rate from 0% to 24%, convertible into the Company’s common stock at a fixed rate of $2.50 per share or at a variable conversion rate upon an event of default
Debt periodic payment		$ 5,835
Debt frequency of periodic payment		for 130 to 140 days
Convertible loans amount						$ 1,011,960
Common stock issued for debt extension, shares		150,000
Convertible loans principal amount		$ 352,188			$ 146,542
Loan period extension		one month
Convertible note amount	$ 98,544
Accrued interest and fees	$ 5,751
Debt conversion, converted instrument, shares	41,718